Understanding how cancer mutations hinder the interactions inside proteins by Sáenz Ausejo, Carmen
 UNIVERSIDAD AUTÓNOMA DE MADRID 
ESCUELA POLITECNICA SUPERIOR 
 
 
               
 
 
 
 
 
Máster Universitario en Bioinformática  
y Biología Computacional 
 
TRABAJO FIN DE MÁSTER 
 
Understanding how cancer mutations 
hinder the interactions inside proteins 
 
Autor: Carmen Sáenz Ausejo 
Tutor: Jose María Gónzalez Izarzugaza  
Ponente: Luis Del Peso Ovalle 
 
 
FEBRUARY, 2018 
 

 
  I 
 
 
 
 
Understanding how cancer mutations 
hinder the interactions inside proteins 
 
Identification of 3D protein clusters as 
potential functional targets applied to BRCA-
mutated breast cancer patients 
 
 
 
 
 
Autor: Carmen Sáenz Ausejo 
Tutor: Jose María Gónzalez Izarzugaza 
Bio and Health Informatics Department, DTU 
Ponente: Luis Del Peso Ovalle 
Biochemistry Department, UAM 
 
 
 
 
FEBRUARY, 2018 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Understanding how cancer mutations hinder the interactions inside proteins	
 
 IV 
	
Summary	
	
	 	
Summary 
The acquisition of somatic mutations can induce cancer by dysregulating the delicate 
mechanisms controlling balance between proliferation and apoptosis. Genomic 
alterations can be classified in driver and passenger mutations. 
Driver mutations confer selective advantage to tumor development, contrarily to 
passenger mutations that do not provide growth advantage to tumorigenesis. Most of the 
driver mutations have unknown functional impact on protein structure and function. 
Furthermore, not all driver alterations in a cancer gene have the same functional 
impact. 
The use of high-throughput sequencing technologies facilitated the discovery of cancer 
related mutations in case and control studies. The analysis of different tumor types 
facilitates the identification of recurrent mutations and the functional pathways involved in 
tumor development.  
One of the current challenges is to distinguish between drivers and passenger 
mutations. Mutations occurring with high frequency in tumor samples are considered to be 
drivers. Therefore, a commonly used method is to consider mutations that occur with 
higher frequency than a background mutation rate.  
 Tamborero et al., (2013) developed a method to identify cancer related genes by 
grouping together residues with a significant rate of mutations that are close in the primary 
sequence of the protein above the background model. The background model was 
generated considering coding-silent mutations based on the evidences of a nonrandom 
mutation processes along the genome (Amos, 2010).  
Recently, Gao et al., (2017) identified genomic mutations affecting residues located in 
3-dimensional proximity of protein structures by comparing the mutation frequency against 
a random background. 
The first method used gene sequences, considering proteins as single strands, and 
omitted that distant genomic regions might be close in the 3D space when the protein folds. 
And the second method assumed a homogeneous mutation probability across the whole 
genome, which is likely an oversimplification that may introduces a bias in the expected 
mutation rates (Amos, 2010). 
Both problems were considered in this study for the development of the algorithm. 
This method identifies associated with BRCA-mutated breast cancer using coding-silent 
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mutation frequency as a background. Furthermore, the method identified structural and 
catalytic roles of 3D protein clusters within relevant biological pathways in breast cancer.  
This method considered that a 3D protein cluster is significant when the residues 
within it have a higher non-synonymous mutation rate as compared to the background 
mutation rate. 
Most of the significant 3D protein clusters were located within PIK3CA gene. 
Additionally, most of the mutations in the 3D clusters were predominantly found in the 
kinase and helical domains of the corresponding protein (PI3K). These mutations 
destabilize the inactive conformation of the proteins or lock the activation loop in an active 
conformation resulting in constitutive protein activation. Thus, significant 3D protein 
clusters in PIK3CA contain ideal hot-spot mutants to target with anti-cancer agents 
(Gabelli, Mandelker, Schmidt-Kittler, Vogelstein, & Amzel, 2010).  
Nowadays, treatments with PI3K inhibitors are available. However, the oncogenic 
PI3K pathway activation is achieved in different redundant ways, therefore mono-therapies 
are not always effective.  
In conclusion, the results of this Master´s Thesis can help to understand better the 
interactions of the non-synonymous mutations in the 3D protein space to identify new 
targets, develop new therapies and consequently maximize the therapeutic benefit. 
 
Key words: Breast cancer, driver mutations, non-synonymous mutations, synonymous 
background model, 3D protein clusters 
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Objectives 
The main goal of this study is to identify 3D protein clusters, rather than cancer-
related genes, containing non-synonymous mutations and annotate them. 
 
The first objective is to understand how cancer mutations hinder the interaction inside 
proteins using synonymous mutations as a background model to identify non-synonymous 
mutations grouped in 3D spatial clusters as potential functional targets in BRCA-mutated 
breast cancer. 
 
Once the significant ones are selected, the second objective is to annotate driver 
clusters with a structural or catalytic role within the protein.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Understanding how cancer mutations hinder the interactions inside proteins	
 
 
 
 
Material and methods 
 
  
2 
Introduction 
Mutations 
Permanent alterations of the nucleotide sequence of the genome are called mutations. 
These can occur during the replication or repair processes, in either somatic or germ-line 
cells. Somatic mutations are not inherited, so they can be disregarded in an evolutionary 
or genetic context (Learn Science at Scitable, 2018). 
Mutations may be classified (Fig.1) by the length of the altered DNA sequence. Here, 
we will focus on those affecting a single nucleotide (single-base or point mutations), 
specifically, on substitution mutations, the replacement of one nucleotide by another. 
Those substitution mutations occurring in protein-coding regions may also be 
classified (Fig.1) according to their effect on the protein. Because the genetic code is 
degenerate, most amino acids are represented by more than one triplet of nucleotide bases. 
These alternative codes for the same amino acid are called synonymous or silent codons.  
Silent mutations are mutations that do not result in a change to the amino acid 
Figure 1. Somatic mutations classified by the length and the effect. 
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sequence of a protein but do change the nucleotide sequence, unless the changed amino-
acid is sufficiently similar to the original. They may occur in a region that does not code 
for a protein, or within a codon in a manner that does not alter the final amino acid 
sequence. While synonymous mutations (Fig.1) occur only within exons and are not 
always silent mutations.  
The terms “synonymous” and “silent” mutation are often used interchangeably 
because, in the great majority of cases, synonymous mutations do not alter the amino acid 
sequence of a protein and are therefore not detectable at the amino acid level. 
Nonsynonymous mutations (amino acid-altering mutations) (Fig.1) are single 
nucleotide changes that cause substitutions of different amino acids, resulting in abnormal 
protein products (Learn Science at Scitable, 2018). Are classified into missense and 
nonsense mutations. The former one changes the affected codon into a codon that specifies 
a different amino acid from the one previously encoded. While the latter one, changes a 
sense codon into a termination codon. These mutations can cause the resulting protein 
nonfunctional. 
Early somatic mutations can cause developmental disorders, whereas the progressive 
accumulation of mutations (P. J. Campbell, Martinocorena, & Campbell, 2015), many of 
which regulate cell division, enable cells enter a state of uncontrolled division, resulting in 
a cluster of cells called tumor. 
Tumorigenesis can be due to alterations in three types of genes: oncogenes, tumor-
suppressor and stability genes, that control cell proliferation, differentiation and cellular 
homeostasis (Vogelstein & Kinzler, 2004). 
- Oncogenes, oncogenic variants of the normal proto-oncogenes that acquired a 
gain-of-function alteration, encode proteins that control cell proliferation, 
apoptosis, or both (Croce, 1995). A somatic mutation is able to cause either an 
alteration in the oncogene structure or an increase in or deregulation of its 
expression (Bishop, 1991), and therefore to confer a selective growth advantage 
on the cell (i.e.: PIK3CA) 
- Tumor-suppressor genes play important roles in suppressing uncontrolled 
proliferation, immortality, and tumorigenicity (i.e.:TP53, PTEN) (Guo, Ngo, 
Modrek, & Lee, 2014). Mutations reduce the activity of the gene product. 
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- Stability genes or caretakers, promotes tumorigenesis in a completely different 
way when mutated. Include genes responsible for repairing subtle mistakes made 
during normal DNA replication or control processes involving large portions of 
chromosomes, such as those responsible for mitotic recombination and 
chromosomal segregation (i.e.: BLM and ATM) (Vogelstein & Kinzler, 2004). 
Stability genes keep genetic alterations to a minimum, and thus when they are 
inactivated, mutations in other genes occur at a higher rate.  
The first somatic mutation in an oncogene or tumor-suppressor gene that causes a 
clonal expansion initiates the neoplastic process (Nowell, 2002). Subsequent somatic 
mutations result in additional rounds of clonal expansion and thus in tumor progression 
(Maley et al., 2004; Vogelstein & Kinzler, 2004). 
All genes are potentially affected by the resultant increased rate of mutation. But only 
can confer a selective growth advantage to the mutant cell those mutations which effect is 
the overexpression of oncogenes and the loss of tumor suppressors (Nowell, 2002). 
Mutations in these genes are the dominant driving forces for tumorigenesis. Hence, 
targeting oncogenes and tumor suppressors hold tremendous therapeutic potential for 
cancer treatment.   
A subset of these somatic alterations, termed driver mutations, confer selective 
growth advantage within a population of cells and are implicated in cancer development. 
Whereas the remainder, passengers mutations, have either no phenotypic consequences or 
biological effects that are not selectively advantageous to the clone (Stratton, Campbell, & 
Futreal, 2009), thus do not contribute to oncogenesis (Pleasance et al., 2010). 
The existence of different types of genes and mutations in cancer has significant 
implications for developing targeted therapies in cancer care (Ye, Pavlicek, Lunney, Rejto, 
& Teng, 2010).  
 
Hot-spots 
While each human tumor has its own unique “genetic signature,” certain oncogenes 
are often found mutated at the same unique positions. These so called “hot-spot” 
mutations can characterize a specific cancer subtype, confer resistance or sensitivity to 
individual inhibitors, and in some cases, correlate with cancer prognosis (Gabelli et al., 
2010). The ideal “hot-spot” mutant to target with anti-cancer agents would have both an 
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activating effect on the protein and exploitable conformational changes when compared to 
its wild-type counterpart.  
Gain-of- function mutations in cancer genes predominantly occur at specific protein 
residues or active domains. An example is PIK3CA in which most mutations are 
predominantly found in the kinase and helical domains of the protein (Karakas, Bachman, 
& Park, 2006). However, remains to be clarified how it can be used to nominate drivers, 
not just gain-of-function cancer genes (Tamborero et al., 2013). 
 
Breast cancer 
In this study, we focus in breast cancer, because is the second leading cause of cancer 
death in women, 1 in 38 (about 2.6%). Only lung cancer kills more women each year. And 
the most common cancer in American women, except for skin cancer, the average risk for 
developing it sometime in her life is about 12% (1 in 8) (American Cancer Society, 2018 ). 
It is therefore important to identify markers that can predict tumor aggressiveness and 
predict the response to the selected therapy at the same time than new functional targets 
can be identified (Børresen-Dale, 2003). 
Death rates from female breast cancer dropped 39% from 1989 to 2015 (Fig. 2) and 
since 2007 have been steady in women younger than 50, but have continued to decrease in 
older women (American Cancer Society,  2018). 
Figure 2. Trends in death rates from 1930 to 2015. Breast cancer is the second cause of cancer death in women in 
United States. Data sources: National Center for Health Statistics (NCHS), Centers for Disease Control and 
Prevention, 2017. Picture taken from American Cancer Society webpage. 
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These decreases are believed to be the result of earlier diagnostic, as well as improved 
treatments, due to the increase on studies that help to understand this disease.  
Mutations in DNA can cause normal breast cells to become cancer. Some of them are 
inherited but most of them are acquired, like lifestyle-related risk factors (what you eat and 
how much you exercise). So these changes, somatic mutations, take place in breast cells 
during a person's life, which can increase the chance of developing breast cancer. But it’s 
not yet known exactly how some of these risk factors cause normal cells to become cancer.  
 
Gene TP53 
Most frequent mutations, in approximately 30% of the tumors, are located in the TP53 
gene (Børresen-Dale, 2003). The frequency of mutations in this gene reported in breast 
tumors ranges from 15 to 71%. 
The phosphoprotein is a transcription factor, which regulates apoptosis, genomic 
stability, and angiogenesis. Functional loss of p53 can lead to defective DNA replication 
and malignant transformation (Levine, 1997).  
The missense mutations usually are between exons 4–10, encoding the DNA-binding 
and oligomerization domain; specifically, along the domain required for interactions with 
FBX042, HIPK1, AXIN1, the DNA major groove, and the domain that contains the 
nuclear export signal (Bai et al., 2014). 
 
Genes BRCA1/2 
BRCA1  (BReast CAncer) and BRCA2 human genes encode tumor suppressor proteins, 
involved in the mechanisms of DNA repair. These genes play a big role in preventing 
breast cancer (National Breast Cancer Foundation, 2018). When mutations in either of 
these genes affect the protein products, DNA damage may not be repaired properly. As a 
result, cells are more likely to develop additional genetic alterations that can lead to cancer.  
Mutations of BRCA1 or BRCA2 genes occur in 0.25% (about 1 in 400) of the 
population (National Breast Cancer Foundation, 2018).  
 
PI3K-Akt-mTOR signaling pathway 
In 2004, Campbell et al. sequenced all of the 20 coding exons of PIK3CA from 
primary tumor samples of breast cancer and suggested that together with other studies 
(Broderick et al., 2004; Saal et al., 2005), the PI3K-Akt-mTOR pathway plays a central 
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role in breast tumorigenesis and implies that this pathway may be an interesting target for 
the development of novel therapies for cancer (I. G. Campbell et al., 2004). 
A better understanding of the pathology of PI3K-Akt-mTOR pathway´s signaling in 
tumors could provide novel therapeutic targets (Parsons, 2004). 
The PI3K-Akt-mTOR signaling pathway (Fig. 3) is a key regulator of cellular 
processes involved in cell growth, proliferation, motility, survival, and apoptosis (Thorpe, 
Yuzugullu, & Zhao, 2015). Alterations of this pathway affect the survival and proliferation 
of tumor cells in many human cancers (Porta, Paglino, & Mosca, 2014). 
Phosphatidylinositol 3-kinases (PI3Ks) are heterodimers, composed of catalytic and 
regulatory subunits, that are activated by growth factor–receptor tyrosine kinases (RTKs) 
(Lewis C. Cantley, 2002; Vanhaesebroeck & Waterfield, 1999). RTKs recruit the catalytic 
Figure 3. Growth factor stimulation of receptor tyrosine kinases triggers PI3K activation, downstream 
activation of phosphoinositide-dependent kinase 1 (PDK1) and AKT, and, subsequently, mTOR 
complex 1 (mTORC1), which promotes cell growth and protein synthesis (2). The pathway can be 
activated by RTKs, G protein-coupled receptors (GPCRs) or by oncogenic proteins such as RAS (Liu et 
al., 2009). The tumor suppressor phosphatase and tensin homolog (PTEN) is a key negative regulator of 
the PI3K pathway (LoRusso, 2016). Picture taken from www.biooncology.com (Genentech website). 
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subunit to the membrane, allowing the activated PI3Ks catalytic subunit to phosphorylate 
the second messenger phosphatidylinositol 4,5-bisphosphate [PI(4,5) P2 or PIP2], 
converting it to phosphatidylinositol 3,4,5-trisphosphate (PIP3) (Lewis C. Cantley, 2002; 
Vanhaesebroeck & Waterfield, 1999), which levels are tightly regulated by the action of 
phosphatases, such as the phosphatase and tensin homolog (PTEN) (Maehama & Dixon, 
1999) (Fig. 3). 
Once at the membrane, PIP3 recruits the serine-threonine protein kinases Akt (also 
called protein kinase B) and phosphoinositide-dependent kinase 1 (PDK1) to the 
membrane. PDK1 consequently phosphorylates and activates Akt (Huang et al., 2007; 
Ikenoue et al., 2005; Ruggero & Sonenberg, 2005). A key protein in the pathway is 
mTOR, that acts both upstream and downstream of Akt, that is active in 2 different 
multiprotein complexes, rapamycin complex (TORC) 1 and 2. In turn, activate numerous 
downstream pathways involved in cell proliferation, survival, motility and growth (Lewis 
C. Cantley, 2002; Carson et al., 2008; Kang, Bader, & Vogt, 2005; Slomovitz & Coleman, 
2012; Vivanco & Sawyers, 2002) (Fig. 3). 
Phosphatidylinositol 3-kinase (PI3K), Akt (a serine/threonine kinase also known as 
PKB), and mammalian target of rapamycin (mTOR) are 3 major junctions in the pathway, 
and are typically activated by upstream signaling of tyrosine kinases and other receptor 
molecules such as hormones (Ruggero & Sonenberg, 2005). 
Aberrant activation of the PI3K-Akt-mTOR pathway is implicated in many human 
tumors (Carson et al., 2008), including breast cancer (Ikenoue et al., 2005). Activation of 
this pathway can be induced by mutations of the PIK3CA gene (encoding the catalytic α-
subunit of PI3K), inactivation of the PTEN tumor suppressor gene, Akt overexpression and 
gene amplification.  The 3 key components of this pathway are PI3K, Akt, or mTOR, 
associated with tumor progression and resistance to cancer therapies when are molecularly 
altered (Chen et al., 2017)(Ikenoue et al., 2005; Myers & Cantley, 2010).  
 
Gene PIK3CA  
Phosphatidylinositol 3-kinases (PI3Ks) are lipid kinases divided in 3 classes, each 
with its own substrate specificity, tissue distribution, and mechanism of action (Cantrell, 
2001; Fruman, 1998; Katso, Okkenhaug, Ahmadi, Timms, & Waterfield, 2001). Class I 
PI3Ks can be further subdivided into two groups (IA and IB) based on their structure and 
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mode of activation (Liu, Cheng, Roberts, & Zhao, 2009; Wymann, Zvelebil, & Laffargue, 
2003). PIK3CA, one of the two most frequently mutated oncogenes in human tumors 
(Gabelli et al., 2010; Liu et al., 2009; Thorpe et al., 2015), codes for p110α, the catalytic 
subunit of PI3Kα (p110α/p85, fig. 4b), that belongs to Class I A heterodimeric PI3Ks 
(Bader, Kang, Zhao, & Vogt, 2005) (Huang et al., 2007). 
The p110α (catalytic subunit of PI3Kα) has five domains (Fig. 4a): an N-terminal 
domain called ABD (adaptorbinding domain) that binds to p85α, a Ras binding domain 
(RBD), a domain called C2 that has been proposed to bind to cellular membranes, a helical 
domain of unknown function, and a kinase catalytic domain (Lewis C. Cantley, 2002; 
Katso et al., 2001; Vanhaesebroeck & Waterfield, 1999; Vivanco & Sawyers, 2002).  
 
The p85α polypeptide (regulatory subunit of PI3Kα) also has five known domains 
(Fig. 4a) including two SH2 domains (the N-terminal nSH2 and C-terminal cSH2) 
separated by an inter-SH2 (iSH2) domain that binds to the catalytic subunit. 
 
 Figure 4. a) PI3K protein is a 
heterodimer: p110α (encoded 
in PIK3CA) and p85α, 
representation of the domains 
in each subunit.  b) PI3K 
protein 3D structure, in blue 
catalytic subunit and in grey 
regulatory subunit. 
 
a 
 
 
 
 
b 
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In its basal state, p85 regulatory subunit stabilizes and maintains p110 catalytic 
subunits of PI3K in a quiescent state until activated by receptor tyrosine kinases (Cheung 
et al., 2014; Cuevas et al., 2001; Yu, Wjasow, & Backer, 1998). When appropriate cellular 
stimuli are present, the nSH2 and cSH2 domains bind phosphorylated tyrosines (Tyr-X-X-
Met motifs) found in activated receptors and adaptor proteins, and this phosphotyrosine 
binding activates the p110 catalytic subunit without releasing p85 from p110. PI3K 
phosphorylates PIP2 and converts it to PIP3 (Ikenoue et al., 2005). 
This structure suggests that p85α regulates p110α activity through a helix aK12–
mediated conformational change of the activation loop (Huang et al., 2007) (Yu et al., 
1998). 
Most of the reported mutations in PIK3CA cluster in conserved regions within the 
region coding for the helical and kinase domains of p110 a (Huang et al., 2007). As these 
mutations constitutively activate its kinase activity, the enzyme appears to be an ideal 
target for drug development. Progress in this area of drug development would be 
facilitated by knowledge of the structure of the p110a/p85a complex. 
 
Gene AKT1 
Akt or protein kinase B, a serine-threonine kinase, is an important downstream 
effector of PI3K (Wan, Harkavy, Shen, Grohar, & Helman, 2007), and one of the most 
frequently activated protein kinases in human cancers (Wan et al., 2007). There are 3 
highly homologous Akt isoforms (Akt 1, 2, and 3) that are encoded by separate genes and 
share over 80% amino acid sequence identity in mammalian cells, with a similar structure: 
an N-terminal PH domain, a central serine-threonine catalytic domain, and a small C-
terminal regulatory domain (Hay, 2005; Liu et al., 2009).  
Binding of Akt to PIP3 occurs at cellular membranes (Kang et al., 2005), resulting in a 
conformational change in AKT, exposing two critical amino acid residues for 
phosphorylation by PDK1 and PDK2 (Liu et al., 2009). 
In cancer, Akt activity is frequently elevated due to oncogenic growth factors, 
angiogenic factors, cytokines, steroid hormones (estrogen and androgen), and genetic 
alterations, including mutations and/or amplifications of the AKT1, AKT2, 
and AKT3 genes; loss of function of the PTEN tumor-suppressor gene; and mutations of 
the PIK3CA gene (Altomare & Testa, 2005; Cheng, Lindsley, Cheng, Yang, & Nicosia, 
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2005; Malanga et al., 2008) .  Hyperactivation of Akt may induce cell growth and 
proliferation, and contribute to apoptotic resistance (Wan et al., 2007). 
 
Gene PTEN 
PTEN is the most important negative regulator of the PI3K-Akt-mTOR pathway by 
dephosphorylating PIP3 second messenger (L C Cantley & Neel, 1999; Cully, You, Levine, 
& Mak, 2006). Can be divided into three domains: a phosphatase domain (1–185), a C2 
domain (186–352), and a tail domain (353–403) (Lee et al., 1999). The phosphatase and 
C2 domains are required for efficient membrane binding. Mutations in the phosphatase 
motif inhibit PIP3 catalysis. The tail domain is an important region for negative regulation 
of PTEN. Deletion of this region activates PTEN’s ability to inhibit Akt  (Parsons, 2004). 
Lack of PTEN in a cell favor tumorigenesis, leading to increase PIP3 and Akt kinase 
activity, thus reduce apoptosis, increase proliferation and alter migration (Parsons, 2004). 
 
Gene mTOR 
Another serine-threonine kinase, mTOR (mammalian target of rapamycin) that exists 
in 2 distinct intracellular complexes: mTORC 1 and 2, plays an important role in the 
regulation of cell growth and proliferation by promoting protein synthesis (Wullschleger, 
Loewith, & Hall, 2006).  
Activation of mTORC1 is achieved through PI3K and Akt (Pópulo, Lopes, & Soares, 
2012). Aberrant activation of mTOR has been implicated in a variety of malignancies, 
including breast cancer (Advani, 2010). 
 
Previous studies 
One of the most known methods to detect positive selection is based on frequency. 
Therefore, a commonly used method is to consider mutations that occur with higher 
frequency than a background mutation rate (Dees et al., 2012; Getz et al., 2007). 
Tamborero et al., (2013) developed a method to identify cancer related genes by 
grouping together residues with a significant rate of mutations that are close in the primary 
sequence of the protein above the background model (Fig. 5). The background model was 
generated considering coding-silent mutations based on the evidences of a nonrandom 
mutation processes along the genome (Amos, 2010).  
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Recently, Gao et al., (2017) identified genomic mutations affecting residues located in 
3-dimensional proximity of protein structures by comparing the mutation frequency against 
a random background (Fig. 6). 
The first method (Fig. 5) used gene sequences, considering proteins as single strands, 
and omitted that distant genomic regions might be close in the 3D space when the protein 
folds. And the second method (Fig. 6) assumed a homogeneous mutation probability across 
the whole genome, which is likely an oversimplification that may introduces a bias in the 
expected mutation rates (Amos, 2010). 
Figure 6. Gao et al., (2017) pipeline.    
Figure 5. Tamborero et al., (2013) pipeline. 
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Both problems were considered in this study for the development of the algorithm. 
This method identifies associated with BRCA-mutated breast cancer using coding-silent 
mutation frequency as a background. Furthermore, the method identified structural and 
catalytic roles of 3D protein clusters within relevant biological pathways in breast cancer.  
The method developed in this study (Fig. 7) considered that a 3D protein cluster is 
significant when the residues within it have a higher non-synonymous mutation rate as 
compared to the background mutation rate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Material and methods 
For the development of the project, as input, this tool requires files stating the position 
of each mutation within the protein sequence to group those ones that are in spatial 
proximity and generate 3D clusters.  
Figure 7. My Master´s Thesis pipeline                      
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The method was applied only to mutational data from BRCA-mutated breast cancer 
patients. The two data sets used (Fig. 8), were obtained from publicly available sources: 
The Cancer Genome Atlas (TCGA) and Catalogue of Somatic Mutations in Cancer 
(COSMIC). In both of them the genomic coordinates of variants were standardized to the 
human reference assembly GRCh38.  
From GDC (Genomic Data Commons) Data Portal, single-nucleotide protein affecting 
mutations were collected from BRCA-mutated breast cancer patients open access dataset 
from The Cancer Genome Atlas (TCGA) (Fig. 9). The data was divided in 986 VCF files, 
every one corresponding to the mutations in each patient, grouped in one MAF file with 
Figure 8. Scheme of the pipeline of my Master´s Thesis  
Understanding how cancer mutations hinder the interactions inside proteins	
 
 
 
 
Material and methods 
 
  
15 
120,988 mutation counts, 61582 were non-synonymous (cancer related), corresponding to 
15587 genes from 986 patients (Annex II). 
The second dataset was downloaded from the Catalogue of Somatic Mutations in 
Cancer (COSMIC, http://www.sanger.ac.uk/cosmic) v78 (Forbes et al., 2016). This 
database contains over 4 million coding mutations across all human cancer disease types, 
of which more than 700,000 are unique coding-silent mutations from 16,460 patients.  
Coding-silent mutations in cancer patients were retrieved to create the background 
model (Annex III).  Coding-silent mutations are assumed not to be under positive selection 
and thus may reflect the baseline tendency of somatic mutations to be clustered.  
 
Identification of 3D protein clusters 
Filtering 
These two filtered datasets by the corresponding mutations were merged, by selecting 
only the synonymous mutations located in those genes with non-synonymous mutations. A 
unique list (Annex II - Ensembl_ID.csv) with the ENSP (Ensembl protein identifier) of 
each protein was obtained. Next, the mutational data was integrated with structural 
information to detect the clusters significantly enriched of cancer related mutations. 
Figure 9. Variant Classification Distribution of BRCA-mutated breast cancer MAF file  
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Selection of the PDB files 
Protein structures (PDB files) with sequence similarity to the Uniprot entries, of 90% 
or above, were included. Sequence similarities were retrieved from the Structure 
Integration with Function, Taxonomy and Sequences (SIFTS) resource (Velankar et al., 
2013). Only PDB files from human wild-type structures with sequence identity of 90% to 
proteins annotated in UniProt were selected (Annex VI). 
From 61,582 ENSPs, 61,136 were found in UniProt (Bateman et al., 2015) but only 
4289 of them had a 3D structure in the Research Collaboratory for Structural 
Bioinformatics (RCSB) Protein Data Bank (PDB, http://www.rcsb.org/) (Berman et al., 
2000), that corresponded to 3,950 proteins (Annexes IV and V). 
For this purpose, structures of the proteins encoded by cancer related genes were 
downloaded and the atomic position of the residues in the proteins was used to generate the 
3D clusters of the protein structures. 
Identification of 3D protein clusters 
Once the selected protein structures were downloaded (Annex VII), contact map of 
residues (Gao et al., 2017) were calculated (Annexes VIII and IX). In this way, 3D protein 
clusters were defined by a central alfa-carbon of a protein residue and all the alfa-carbon of 
residues within 15 angstroms (Å). All residues were used as centers of clusters and the 3D 
cluster score was computed separately for each cluster. Each residue can appear in more 
than one cluster. We obtained 1,125,682 3D protein clusters in total.  
 
Computation of cluster mutation frequencies 
The genomic position of each mutation and the corresponding mutant count were 
mapped and assigned to the sequence position of the encoded amino-acid (Annexes IX and 
X), thus to each 3D protein cluster. 
Then the non-synonym (NS) and synonym (S) mutation frequencies (1, 2) were 
computed with the mutant counts as shown below: 
 𝑁𝑆 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 =  𝑁𝑆 𝑚𝑢𝑡𝑎𝑛𝑡 𝑐𝑜𝑢𝑛𝑡𝑠 ∗ 𝑐𝑎𝑠𝑒𝑠 ∗ 𝑙𝑒𝑛𝑔𝑡ℎ 𝑆 𝑓𝑟𝑒𝑞𝑢𝑒𝑛𝑐𝑦 =  𝑆 𝑚𝑢𝑡𝑎𝑛𝑡 𝑐𝑜𝑢𝑛𝑡𝑠 ∗ 𝑐𝑎𝑠𝑒𝑠 ∗  𝑙𝑒𝑛𝑔𝑡ℎ 
 
 
(1) 
(2) 
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where NS mutant counts represents the number of times that a cancer related (non-
synonymous) mutation appears in a position in the BRCA dataset. The same way, S mutant 
counts represents the number of times that a coding-silent (synonymous) mutation appears 
in a position in the COSMIC dataset. Cases is the number of patients in the database 
(16,460 for COSMIC dataset and 10,188 for GDC dataset), even there are 986 BRCA-
mutated breast cancer patients, we use the total number of cases in the dataset. Length is 
the number of residues in the cluster. To do comparable the frequencies, the length of the 
cluster is multiplied to the length of the cluster, because is not the same two mutations in a 
cluster of 15 residues than in a cluster of 30 residues.  
 
Computation of the 3 D protein score 
The 3D cluster score is computed (Annex XI) as (3): 
 3𝐷 𝑐𝑙𝑢𝑠𝑡𝑒𝑟 𝑠𝑐𝑜𝑟𝑒 =  !" !"#$%# !"#$%&∗!"#$#∗!"#$%! ! !"#$%# !"#$%&∗!"#$#∗!"#$%! = !" !"#$%#&'(!  !"#$%#&'(    
 
The 3D cluster score is directly proportional to the frequency of non-synonym 
mutations of the residues in the cluster and inversely proportional to the frequency of 
synonym mutations in the cluster. The number of residues in each cluster does not affect 
the 3D cluster score since the frequency of synonyms and non-synonyms mutation are 
computed in the same set of residues. 
There are two reasons why the 3D cluster score was computed as simple ratio: i) the 
distribution of the synonym mutation frequencies is not normal therefore a Z-score cannot 
be applied, ii) genomic regions with no mutations annotated generate frequency of value 0 
that are called structural zeroes. The presence of structural zeroes limits the application of 
statistical methods.  
The presence of structural zeroes does not allow the computation of 3D cluster scores. 
Therefore, a pseudo-count (10-10) was added to each mutant count. 
The clusters were ranked based on the 3D cluster score after log2 transformation in 
order to make the frequencies comparable (same scale).  
All the algorithms were written in Python or R languages (Annexes II-XI). The entire 
bioinformatics pipeline was executed in Computerome (Danish National Supercomputer 
for Life Science). 
(3) 
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Visualization of 3D protein clusters 
The 3D structures of proteins with a high number of significant 3D cluster scores were 
further analyzed with PyMOL, a free cross-platform molecular graphics system.  
PyMOL is very useful when working with proteins, because it allows localizing the 
aminoacids in a 3D space. Therefore, PyMOL allows the visualization of non-synonymous 
mutations of significant 3D protein clusters within the 3D protein structure. This gives 
information about how the residues interact and how the mutations can affect the structure 
and also to the functionality of a protein (see Results).  
 
Results  
Analysis of the ratio between non-synonymous and synonymous mutation frequencies 
is a good measure of positive selection during tumor progression, as synonymous 
alterations are unlikely to exert a growth advantage.  
Somatic mutations were collected and merged from two different databases. The 
dataset from TCGA with mutations of BRCA-mutated breast cancer patients, contained 
120,988 mutation counts, 61,582 of them were non-synonymous (cancer related) located in 
15,587 genes from 986 patients. The second dataset was from COSMIC, with more than 4 
million coding mutations across all human cancer disease types, of which more than 
700,000 mutations are unique synonymous alterations from 16,460 patients.  
Figure 10. Representation of the difference between the number of ENSP founded in Ensembl 
and the number of PDB files founded in RCSB. Due to a lack of complete protein structure data, 
some of the PDB files included only individual protein domains. 
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These datasets contains the position of each mutation within the protein sequence to 
group those ones that are in spatial proximity and generate 3D clusters. 
From 61,582 ENSPs in common between the two datasets, 61,136 were found in 
UniProt (Bateman et al., 2015) but only 4,289 of them had a 3D structure in the Research 
Collaboratory for Structural Bioinformatics (RCSB) Protein Data Bank (PDB, 
http://www.rcsb.org/) (Berman et al., 2000), that corresponded to 3,950 proteins (Fig. 10).  
The difference between the number of ENSP that we had at the beginning (Fig. 10) 
and the reduced number of 3D structures corresponding to the proteins of some of them, is 
because we only selected those PDB files from human wild-type structures with 90% of 
sequence identity to proteins annotated in UniProt (see Materials and methods).  
When the method developed in this study was applied to BRCA-mutated breast cancer 
patients, more than 1 million 3D protein clusters (1,125,682) located in 3,950 proteins 
were generated. Then, these clusters were ranked based on the log2 3D cluster scores as 
shown in the graph below (Fig. 11).  
Due to the pseudo-counts added to each mutant count, the shape of the graph was 
expected. And it highlighted those 3D protein clusters with only one kind of alterations, 
Figure 11. The 3D cluster score is a ratio. The log2 of it equals 1 when the frequencies for synonymous and non-
synonymous mutations in a cluster are the same. Values lower than 1, right side of the graph, are those spatial 
clusters with higher synonymous mutation frequencies. And values higher than one, left side of the graph, 
correspond to the spatial clusters with higher non-synonymous mutation frequencies.  
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synonymous or non-synonymous mutations, located at the extremes of the distribution 
(Fig. 11).  
In this analysis, we focused on the left side of the graph (Fig. 11), where we expected 
to find the 3D protein clusters that contained potential functional targets. The 3D protein 
clusters with a value higher than 1, indicate a positive selection, mutations that can benefit 
the cell proliferation and tumorigenesis development. However, not all this alterations in 
cancer genes are driver alterations. Furthermore, not all driver alterations in a cancer 
gene have the same functional impact. 
We expected to find three types of clusters: i) with mutations close in the sequence, ii) 
containing mutations far in the sequence but within the same domain and iii) with grouped 
mutations that are localized in different domains, thus far in the sequence. This last one is 
the most interesting because mutations that are not close in 1D protein sequence cannot be 
easily related. Identifying interactions of non-synonymous mutations, localized in different 
domains but close in the 3D protein space, can contribute to identify new targets, develop 
new therapies and consequently maximize the therapeutic benefit (Fig.7). 
Even 1 million of 3D protein clusters were computed, only 1,363 with values higher 
than 5, were considered significant. These clusters were localized in 27 genes and with a 
3D structural representation in 28 PDB files. Two of these 3D structures included only 
individual protein domains, not the complete protein structure. 
In this BRCA-mutated breast cancer dataset, many of the significant 3D cluster scores 
were identified in two well-characterized cancer genes: PIK3CA (Fig. 12) and TP53 
(Annex I). Other significant 3D protein clusters were localized in AKT1 and PTEN genes 
(Annex I). All of them related with tumorigenesis development and cancer implications 
and involved in PI3K-Akt-mTOR pathway. 
 
PIK3CA 
The oncogenic potential of the PI3K pathway is explained by two key observations. 
First, alterations in the PI3K/AKT/mTOR pathway can induce cell line transformation and 
tumor formation in transgenic mice (Carver et al., 2011; Engelman et al., 2008). Second, 
PI3K signaling activation frequently occurs following multiple molecular alterations in 
other components of the pathway downstream of PI3K, such as mutations in PIK3CA, 
AKT1 and PTEN genes. 
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Most of the significant 3D protein clusters located in the left side of the graph 
corresponded to the gene PIK3CA (Fig. 12). When computing the ratio between non-
synonymous to synonymous mutations, in this gene, there is a prevalence for non-
synonymous changes above the background model. 
 Non-synonymous mutations in PIK3CA gene have been reported in many human 
cancer types (Karakas et al., 2006), and in breast cancer, most mutations occur in this gene. 
In 2016, LoRusso published that approximately 20% to 50% of breast cancers exhibit 
PIK3CA mutations. Three frequent hotspot mutations (Fig. 13) within the helical (E545K 
and E542K in exon 9) and kinase domains (H1047R in exon 20) result in constitutive 
p110a (catalytic domain of PI3K) activity (Karakas et al., 2006; LoRusso, 2016).  
In addition to these three hot spots, there are several cancer-specific mutations that 
have been shown to result in enhanced enzymatic activity of PI3K in vitro and in vivo 
(Huang et al., 2007; Ikenoue et al., 2005; Kang et al., 2005; Samuels et al., 2004): 
- ABD domain mutations: (residues R38 and R88) the structure of the p110a/niSH2 
reveals that both Arg38 and Arg88 are located at a contact between the ABD and the 
kinase domains. 
- Mutations in the C2 domain: (residues N345 and E453) mutations in both residues 
may disrupt the interaction of the C2 domain with iSH2 and alter the regulatory effect 
of p85 on p110a.  
- Helical domain mutations: (residues E542, E545 (hotspots) and Q546) mutations in 
these residues, located on an exposed region, can cause a charge reversal. Interaction 
Figure 12. Distribution of log2 3D cluster scores, highlighted in red the 3D cluster scores within PIK3CA gene  
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with residues of nSH2, p85 domain, alter the activity of the catalytic subunit (Miled et 
al., 2007; Yu et al., 1998). Mutations may modify the orientation of nSH2 with respect 
to the helical and the kinase domains. 
- Kinase domain mutations: (residues H1047 (hotspot) and M1043) residue H1047 is a 
hot spot for somatic mutations in cancer. Mutations in this residue can change the 
interaction between the activation loop and the substrates. Several studies have shown 
support for the hypothesis that activating somatic mutations tend to cluster in protein 
kinases (Dixit et al., 2009; Greenman et al., 2007; Izarzugaza, Redfern, Orengo, & 
Valencia, 2009). 
In this study, not all of the mutated residues were founded, such as residue 453; or had 
a low mutation frequency, fewer than 5 mutation counts, such as residues 38, 88 and 379. 
Furthermore, residues with high mutation frequencies in this dataset, located in positions 
420 and 452, are not considered as breast cancer-specific mutations in previous studies. 
Could be possible functional targets in future studies, because there are located close to 
residue E453, an already known important cancer-specific mutation. 
As the distribution represents (Fig. 13), the three mutations with higher non-
synonymous mutant counts are located in residues: H1047, E545 and E542. In particular, 
H1047R mutation is located in the kinase domain near the binding region of the activation 
Figure 13. Representation of significant non-synonymous mutations (>5 mutant counts) in PIK3CA 
residues in BRCA-mutated breast cancer patients of TCGA dataset. 
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loop. Is postulated to enhance the catalytic activity of the enzyme by locking the loop in 
the ‘on’ position. On the other hand, alterations in E542K and E545K are localized in the 
helical domain. These mutated residues are clustered into an exposed region and might 
interact with the cellular membrane (Carson et al., 2008). Therefore, these mutations 
cause increased lipid kinase activity (2-fold increase, Carson et al., 2008) by allowing 
easier access to the membrane-bound PIP2 substrate, which is then converted to PIP3, 
initiating tumorigenic signaling cascades (Karakas et al., 2006; Mandelker et al., 2009).  
The most significant 3D cluster scores of PIK3CA included the three hotspots. As it is 
expected, mutations in the helical domain, E545 and E542, are clustered together (Fig. 14) 
due to the proximity in the sequence. But, we also founded that mutations in residues E542 
(helical domain) and H1047 (kinase domain), where grouped together (Fig. 15) in the same 
cluster. This one is very interesting, because contains two hotspots localized far in the 
sequence, in different domains, but close in the 3D spatial protein structure.  
Also, it is important to highlight, even some of these mutations can be identified by 
their mutation frequency in a single position, and others are less common, below 5 mutant 
counts. These rare mutations commonly located in 3D proximity to hotspots or to a known 
and common mutation in the same protein, can be considered as possible driver events.  
Figure 14. 3D visualization of two of the hotspots, residues E542 and E545, in PIK3CA gene highlighted 
with red arrows 
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Discussion 
Importance of this study 
The acquisition of somatic mutations can induce cancer by dysregulating the delicate 
mechanisms controlling balance between proliferation and apoptosis. Genomic 
alterations can be classified in driver and passenger mutations. 
Most of the driver mutations have unknown functional impact on protein structure and 
function. Furthermore, not all driver alterations in a cancer gene have the same 
functional impact. Identification of driver mutations among the passenger mutations in 
patient genomes it is necessary for effective development and use of targeted therapies. 
The use of high-throughput sequencing technologies facilitated the discovery of cancer 
related mutations in case and control studies. The analysis of different tumor types 
facilitates the identification of recurrent mutations and the functional pathways involved in 
tumor development.  
Figure 15. 3D visualization of two of the hotspots, residues E542 and H1047, in PIK3CA gene 
highlighted with red arrows 
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Many of the somatic mutations can be identified by their frequencies in a single 
position, but others are less common. This less frequent mutations commonly located in 
3D proximity to hotspots or to a known and common mutation in the same protein, have 
the possibility that are also driver events.  
This method enabled the identification of significant 3D protein clusters containing 
non-synonym mutations that are relatively far away in linear space but relatively close 
together in 3D space. The results gave useful information about interactions between 
residues or domains. The identification of affected pathways can help to understand better 
the effect of non-synonymous mutations in the tertiary structure of proteins and to identify 
new targets, develop new therapies and consequently maximize the therapeutic benefit. 
 
Limitations 
While our approach can identify interesting mutations grouped in 3D protein clusters 
as targets, the method is still limited by the lack of complete protein structure data for 
many genes. For the 61,582 genes with synonym and non-synonym mutations in our 
dataset, we were able to align 61,136 of them to one or more protein structures. But only 
analyzed 3,950 genes, corresponding to 4,289 PDB files with a protein structure that 
covered more than 90% of the protein length and with a human wild-type structure. Some 
of the structures only included individual protein domains, so interaction between different 
regions cannot be related if them are in different PDB files. This limits the ability of our 
algorithm to detect mutated residues grouped in 3D clusters that were not close in 
sequence, for example, those involved in domain-domain interactions.  
Furthermore, most of the genes do not even have a protein structure, like BRCA1 or 
BRCA2, important proteins in the BRCA-mutated breast cancer dataset. PDB files of these 
proteins would have been very interesting to see how non-synonymous mutations are 
clustered in the 3D space and the interaction between these residues.  
Like any statistical method, the power of our approach is also limited by the 
number of available tumor samples. Fortunately, as more cancer genomic data are 
generated, additional significant 3D clusters will likely emerge. 
Another methodological difference was the distance cutoffs that were used to 
decide whether two residues are interacting in 3D structures. In this study, the 3D 
protein clusters were defined within a diameter of 15Å from a central alfa-carbon of a 
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protein residue, while in Gao et al. (2017) study the selected distance was 5Å. 
The most important difference between this study and the previous ones is that 
previous studies considered proteins as single strands, and omitted that distant genomic 
regions might be close in the 3D space when the protein folds. 
Another important difference is that these methods described before assumed that 
mutation probability is homogeneous across the gene sequence, which is likely an 
oversimplification that introduces a bias in the analysis.  
We identified significant mutated 3D-clusters above coding-silent mutations as a 
background, to determine the significance of our observations. These genomic alterations 
are assumed not to be under positive selection and thus may reflect the baseline tendency 
of somatic mutations to be clustered.  
A critical step for the choice of therapy, design of clinical trials, or drug 
development is to localize non-synonymous mutations in the 3D space and to identify 
significant 3D protein clusters containing these cancer-related alterations. 
 
Conclusion 
The elucidation of cancer drivers relies on identifying the marks of positive selection 
that occur during the clonal evolution of tumors. The trend shown by protein-affecting 
mutations to accumulate predominantly in certain gene regions is a fingerprint that may 
denote events targeted by the tumorigenesis. 
For this reason, we propose to construct the background model using synonymous 
mutations, which are assumed not to be under positive selection and may thus reflect the 
baseline mutation clustering of the tumor. This assumption also probably comprises a 
simplification because some coding-silent mutations could in principle alter processes such 
as chromatin remodeling or mRNA processing. Nevertheless, apart from this, they are not in 
general functionally involved in tumorigenesis.  
Once the background model was created, non-synonymous mutations were mapped to 
the protein sequence and grouped together in the 3D space, taking into account the 
tertiary conformation of the protein. 
The significant 3D protein clusters where selected and we provided a mechanistic 
explanation to some of them. 
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PIK3CA is the gene where most of these 3D clusters where localized. H1047R is an 
ideal hot-spot mutant to target because has an activating effect on the protein and exploitable 
conformational changes when compared to its wild-type counterpart.  
Initial PI3K-directed drugs in clinical trials, consisting largely of non-isoform-selective 
pan-PI3K inhibitors, have not provided exciting results. However, recent preclinical studies 
have demonstrated that different PI3K isoforms play divergent roles in cellular signaling and 
cancer, suggesting that inhibitors targeting individual isoforms may be able to achieve 
greater therapeutic efficacy (Thorpe et al., 2015). 
Nowadays, treatments with PI3K inhibitors are available. Because the oncogenic 
PI3K-Akt-mTOR pathway activation is achieved in different redundant ways, these mono-
therapies are not always effective. Treatments have been limited requiring adapted 
strategies in each tumor type (LoRusso, 2016) and PI3K inhibitor combinations generally 
result in cumulative, nonspecific toxicities. 
For future development, it would be very interesting to experimentally validate the 
potential 3D clusters, which include the main driver and some of the low frequent mutations 
localized close to them. Also, to apply this method to all type of cancers, to find potential 
targets common in all of them or specific for each type. These results would implicate new 
therapies or personalized treatments, focusing on potential targets on pathways than in 
individual genes. 
 
This Master Thesis project allowed me to deal with the main aspects of the 
bioinformatics research such as: i) use public databases and cancer repositories, ii) parsing 
of data file, the integration of different type of dataset (protein annotation, structures, 
sequences and genomic data), iii) use of different programming languages (R, python) in a 
high performance cluster (Computerome, #182 supercomputer in the world) iv) analysis of 
big dataset and deal with computational time issues, v) use 3D protein structure visualization 
tools, vi) identification of the most suitable statistical approaches and vi) biological 
interpretation of the results. 
Furthermore, to complete successfully the project I had to collaborate with different 
researchers within the work environment. 
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Annex 1. Distribution of log2 3D cluster scores of the most significant 3D protein clusters in BRCA-
mutated breast cancer dataset 
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Annex II 
## 1- Breast_MAF.R 
################################################################### 
## DTU - Department of Bio and Health Informatics 
## 2017 
## Carmen Saenz 
## 
## 1. Load libraries 
## 2. Set directory 
## 3. Load data - BRCA-mutated Breast cancer 
## 4. Filter data 
## 5. Save output 
## 
###################################################################  
# Load Libraries 
################################################################### 
source("http://bioconductor.org/biocLite.R") 
biocLite("maftools") 
biocLite("Rsamtools") 
 
# Load required libraries but suppressing the Package Startup Messages (this is in case you 
want to embed this inside  
# an automated script) to avoid flooding the terminal with non interesting messages. 
suppressPackageStartupMessages(library(Rsamtools)) 
suppressPackageStartupMessages(library(maftools)) 
suppressPackageStartupMessages(library(dplyr)) 
 
# Load libraries 
library(Rsamtools) 
library(maftools) 
library(dplyr) 
library(data.table) 
 
###################################################################  
# Set directory 
################################################################### 
 
setwd("") #Set directory 
 
###################################################################  
# Load Data 
###################################################################  
###                           GDC                               ### 
###                   BRCA-mutated Breast Cancer Data           ### 
###################################################################  
 
start.time <- Sys.time() 
 
### READ maf file 
# INPUT: MAF file BRCA-mutated breast cancer data from: https://portal.gdc.cancer.gov/ 
maf_data <- maftools::read.maf(maf="./MAF/TCGA.BRCA.somatic.maf", removeSilent = F, useAll 
= F) 
 
# Save maf file as data frame 
breast_data = maf_data@data 
 
### FILTER and SORT data. Synonym and Non Synonym  
#Sort data by Variant_Classification  
breast_data = breast_data[with(breast_data, order(Variant_Classification))] 
#Filter data by synonymous or non synonymous variation 
synonym <- filter(breast_data, Variant_Classification == "Silent") 
write.table(synonym, "./GDC-maf/BreastData_Synonym.csv", sep = "\t", row.names = FALSE) # 
used in 2-Somatic_TSV.R 
non_synonym <- filter(breast_data, Variant_Classification == "Missense_Mutation", 
Variant_Type == 'SNP') 
write.table(non_synonym, "./GDC-maf/BreastData_NonSynonym.csv", sep = "\t", row.names = 
FALSE) 
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### Ensembl IDs (ENSP = idemtifiers for Proteins) list - ENSP  of the genes with Non 
Synonymous mutations 
# Data frame gene symbol, Ensembl ID, DNA and protein mutation position of non synonymous 
variations 
ns_df <- select(non_synonym, Hugo_Symbol, ENSP) 
#DNA Change column 
df <- select (non_synonym, Chromosome, Start_Position, Tumor_Seq_Allele1, 
Tumor_Seq_Allele2) 
ns_df$DNA_Change <- paste0(df$Chromosome, ":g.", df$Start_Position, df$Tumor_Seq_Allele1, 
">", df$Tumor_Seq_Allele2) 
#Protein Change columns 
library(stringr) 
split <- as.data.frame(str_match(non_synonym$HGVSp, "^(p).(.{3})(.*)(.{3})")[,-1]) 
# Add the two columns to ns_df 
ns_df$HGVSp <- non_synonym$HGVSp_Short 
ns_df$aa <- split$V2 
ns_df$aa_mut <- split$V4 
ns_df$prot_position <- split$V3 
 
# Filter data frame, save unique values 
ns_df_u <- ns_df[!duplicated(ns_df), ] 
write.table(ns_df_u, "./NS_aa_position.csv", sep = "\t", row.names = FALSE) 
 
# List of Ensembl IDs  
ensembl_id <- unique(data.frame("ENSP_ID" = ns_df_u$ENSP)) 
 
# Save data frame and list with Ensembl IDs 
write.csv(ensembl_id, "./EnsemblP_ID.csv", row.names = FALSE)  # used in 4-ENSP_PDB_NS.py 
 
###################################################################  
# Filter Data 
###################################################################  
#Mutation frequency  
#Filter data by Non Synonymous variation 
mutation_freq_NS <- fread('./Data/GDC/Breast/TSV/Mutation_freq/Breast_freq_NS.csv') 
 
split_freq <- as.data.frame(str_match(mutation_freq_NS$Affected_cases_Cohort, 
"^(.*)/(.*),(.*%)")[,-1]) 
split_freq2 <- as.data.frame(str_match(mutation_freq_NS$Affected_cases_GDC, 
"^(.*)/(.*)")[,-1]) 
split_freq2$V2 <- gsub(',', '', split_freq2$V2) 
mutation_freq_NS$Mutation_count <- split_freq$V1 
mutation_freq_NS$Frequency_BRCA <- split_freq$V3 
mutation_freq_NS$Total_cases_Cohort <- split_freq$V2 
mutation_freq_NS$Frequency_GDC <- (as.integer(mutation_freq_NS$Mutation_count)/(as.integer( 
split_freq2$V2))*100) 
mutation_freq_NS$Frequency_GDC <- round(mutation_freq_NS$Frequency_GDC, 4) 
mutation_freq_NS$Frequency_GDC <- paste(mutation_freq_NS$Frequency_GDC,'%') 
mutation_freq_NS$Total_cases_GDC <- split_freq2$V2 
mutation_freq_NS <- select(mutation_freq_NS, DNA_Change, Consequences, Mutation_count, 
Frequency_BRCA, Total_cases_Cohort,  
                           Frequency_GDC, Total_cases_GDC) 
 
# MERGE  
breast_NS <- merge(ns_df_u, mutation_freq_NS, by= c("DNA_Change")) 
 
###################################################################  
# Save Data 
###################################################################  
breast_NS <- select(breast_NS, Hugo_Symbol, ENSP, DNA_Change, HGVSp, aa, aa_mut, 
prot_position, Consequences, Mutation_count, 
                    Frequency_BRCA, Total_cases_Cohort, Frequency_GDC, Total_cases_GDC) 
write.csv(breast_NS, "./Breast-NS_freq.csv", row.names = FALSE) # used in 4-ENSP_PDB_NS.py 
 
end.time <- Sys.time() 
time.taken <- end.time - start.time 
print('Done!') 
print(paste('Time:', time.taken, 'seconds')) 
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Annex III 
## 2- Somatic_TSV.R 
################################################################### 
## DTU - Department of Bio and Health Informatics 
## 2017 
## Carmen Saenz 
## 
## 1. Load libraries 
## 2. Set directory 
## 3. Load data - Synonymous mutations - background 
## 4. Filter data 
## 5. Load data - Non-synonymous mutations - BRCA-mutated Breast cancer 
## 6. Merge data 
## 7. Save output 
## 
################################################################### 
# Load Libraries 
################################################################### 
suppressPackageStartupMessages(library(dplyr)) 
library(dplyr) 
library(data.table) 
 
###################################################################  
# 
# Set directory 
# 
################################################################### 
setwd("") 
################################################################### 
# Load Data 
################################################################### 
###                         COSMIC                              ### 
###           (Background - Synonymous mutations)               ### 
###             CosmicGenomeScreensMutantExport                 ### 
################################################################### 
start.time <- Sys.time() 
 
#Big file --> 1.2GB 
background <- fread('./COSMIC/CosmicGenomeScreensMutantExport.GRCh38.tsv') # (4452018 
somatic mutations) 
 
################################################################### 
# Filter Data 
################################################################### 
# Data frame gene symbol, Ensembl ID, Patient ID, DNA and protein mutation position of 
synonymous variations 
background_S <- background[background$`Mutation Description` == 'Substitution - coding 
silent']  
# (1031615 synonym mutations) 
background_S <- select(background_S, `Gene name`, `Accession Number`, `Sample name`, 
`Mutation CDS`, `Mutation AA`,  
                       `Mutation genome position`) 
colnames(background_S) <- c('Gene_name', 'ENST', 'Sample_ID', 'Mutation_CDS', 'HGVSp', 
'Mutation_genome_pos') 
 
# Make variables from synonymous and non-synonymous files comparables 
library(stringr) 
split_gene_name <- as.data.frame(str_match(background_S$Gene_name, "^(.*)(_.*)")[,-1]) 
background_S$Hugo_Symbol <- as.character(split_gene_name$V1) 
background_S$Hugo_Symbol[is.na(background_S$Hugo_Symbol)] <- 
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as.character(background_S$Gene_name[is.na 
                                                                                                 
(background_S$Hugo_Symbol)]) 
split_chr_pos <- as.data.frame(str_match(background_S$Mutation_genome_pos, "^(.*):(.*)-
(.*)")[,-1]) 
split_mut <- as.data.frame(str_match(background_S$Mutation_CDS, "^(.*)(.>.)")[,-1]) 
background_S$DNA_Change <- paste('chr',split_chr_pos$V1,':g.', 
split_chr_pos$V2,split_mut$V2, sep = "") 
 
split_id <- as.data.frame(str_match(background_S$Sample_ID, "^(TCGA-.{2}-.{4})-(.{2})")[,-
1]) 
background_S$Patient_ID <- as.character(split_id$V1) 
background_S$Patient_ID[is.na(background_S$Patient_ID)] <- 
as.character(background_S$Sample_ID[is.na(background_S$Patient_ID)]) 
background_S <- select(background_S, 'Hugo_Symbol', 'ENST', 'DNA_Change', 'HGVSp', 
'Patient_ID') 
 
background_S_cases <- as.integer(length(unique(background_S$Patient_ID))) # (16328 cases) 
 
################################################################### 
# Load Data 
################################################################### 
# 
###                           GDC                               ### 
###          Breast Data - Synonym mutations                    ### 
# 
###################################################################  
 
Breast_synonym <- fread('./GDC-maf/BreastData_Synonym.csv') # From 1.A-Breast_MAF.R script 
 
# Data frame gene symbol, Ensembl ID, DNA and protein mutation position of non synonymous 
variations 
s_df <- select(Breast_synonym, Hugo_Symbol, Transcript_ID) 
colnames(s_df) <- c('Hugo_Symbol', 'ENST') 
#DNA Change column 
df <- select (Breast_synonym, Chromosome, Start_Position, Tumor_Seq_Allele1, 
Tumor_Seq_Allele2) 
s_df$DNA_Change <- paste0(df$Chromosome, ":g.", df$Start_Position, df$Tumor_Seq_Allele1, 
">", df$Tumor_Seq_Allele2) 
s_df$HGVSp <- Breast_synonym$HGVSp_Short 
split_id_GDC <- as.data.frame(str_match(Breast_synonym$Matched_Norm_Sample_Barcode, 
"^(TCGA-.{2}-.{4})-(.*)")[,-1]) 
s_df$Patient_ID <- as.character(split_id_GDC$V1) 
 
#################################################################### 
# Merge Data 
################################################################### 
# Merge both datasets (TCGA BRCA synonym mutations that are not in COSMIC datset) --> 
(#1044803) 
not_common <- anti_join(background_S, s_df, by = c("DNA_Change", "Patient_ID")) ##1022412 
Synonym <- merge(not_common, s_df, all = TRUE) #1044803 
 
#library(plyr)#If you need functions from both plyr and dplyr, please load plyr first, then 
dplyr. 
Freq <- Synonym %>% plyr::count(c('DNA_Change', 'HGVSp')) 
 
####### Add to S_freq hugo_symbol and ENST variables 
S_freq <- merge (Freq, Synonym, by=c('DNA_Change', 'HGVSp')) 
background_S_cases <- as.integer(length(unique(S_freq$Patient_ID))) # (16460 cases) 
S_freq$Mutation_count <- S_freq$freq 
S_freq$Frequency <- ((S_freq$freq/(as.integer(background_S_cases)))*100) 
S_freq$Frequency <- round(S_freq$Frequency, 4) 
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S_freq$Frequency <- paste(S_freq$Frequency,'%') 
S_freq$Total_cases_COSMIC <- background_S_cases 
 
####### Convert aa names from 1 letter to 3 
library(stringr) 
split_aa <- as.data.frame(str_match(S_freq$HGVSp, "^(p).(.)(.*)(.)")[,-1]) 
code = data.frame(aa_1 = c('A', 'R', 'N', 'D', 'B', 'C', 'E', 'Q', 'Z', 'G', 'H', 'I', 'L', 
'K', 'M', 'F', 'P', 'S',  
                           'T', 'W', 'V', 'Y'),  
                  aa_3 = c('ALA', 'ARG', 'ASN', 'ASP', 'ASX', 'CYS', 'GLU', 'GLN', 'GLX', 
'GLY', 'HIS', 'ILE', 'LEU',  
                           'LYS', 'MET', 'PHE','PRO', 'SER', 'THR', 'TRP', 'VAL', 'TYR')) 
 
split_aa$V5 <-as.vector(code[match(split_aa$V2, code$aa_1),2]) 
split_aa$V6 <-  as.vector(code[match(split_aa$V4, code$aa_1),2]) 
 
S_freq$aa <- split_aa$V5 
S_freq$aa_mut <- split_aa$V6 
S_freq$prot_position <- split_aa$V3 
 
S_freq <- select(S_freq, 'Hugo_Symbol', 'ENST', 'DNA_Change', 'HGVSp', 'aa', 'aa_mut', 
'prot_position',  
                 'Mutation_count', 'Frequency', 'Total_cases_COSMIC') 
background_S_u <- S_freq[!duplicated(S_freq[,c('DNA_Change', 'HGVSp')]),] 
write.csv(background_S_u, './Breast-S_freq.csv', row.names = FALSE) 
 
# List of Ensembl IDs - ENST 
ensembl_id <- data.frame("ENST_ID" = unique(S_freq$ENST)) # (29356 ENST) # used in 3-
ENST_PDB_S.py 
 
#################################################################### 
# Save Data 
################################################################### 
# Save data frame and list with Ensembl IDs 
write.csv(ensembl_id, "./EnsemblT_ID.csv", row.names = FALSE)  # used in 3-ENST_PDB_S.py 
 
end.time <- Sys.time() 
time.taken <- end.time - start.time 
print('Done!') 
print(paste('Time:', time.taken, 'seconds')) 
Annex IV 
## 3- ENST_PDB_S.py 
# --------------------------------------------------------------- 
## DTU - Department of Bio and Health Informatics 
## 2017 
## Carmen Saenz 
## 
## 1. Load libraries 
## 2. Load data - Ensembl ID and mutation counts synonymous mutations 
## 3. Filter data 
## 4. Merge data 
## 5. Save data 
## 
# --------------------------------------------------------------- 
# Load Libraries 
# --------------------------------------------------------------- 
 
from bioservices import UniProt 
import numpy as np 
import pandas as pd 
from time import time 
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ini_time = time() 
# --------------------------------------------------------------- 
# Load data 
# --------------------------------------------------------------- 
Synonymous_df = pd.read_csv('./EnsemblT_ID.csv', sep='\t') #From 2-Somatic_TSV.R 
 
#   Convert ENST ID column to a list 
ensembl_id = Synonymous_df['ENST_ID'].tolist() 
# --------------------------------------------------------------- 
# ENST in UniProt 
# --------------------------------------------------------------- 
u = UniProt(verbose=False) 
 
#   ID mapping UniProt 
uniprot_id = u.mapping(fr = 'ENSEMBL_TRS_ID', to ='ACC', query = ensembl_id) 
#print (uniprot_id) 
 
#   Select only UniProt IDs 
uniprot_dic = {} 
uniprot_list = [] 
ensembl_id_2 = [] 
 
for element in uniprot_id: 
    uniprot_dic[element] = uniprot_id[element][0] 
    id = uniprot_id[element][0] 
    uniprot_list.append(id) 
    ensembl_id_2.append(element) 
 
uniprot_inv_dic = {v: k for k, v in uniprot_dic.items()} 
 
#   Save only non duplicate UniProt IDs 
uniprot_list = set(uniprot_list) 
 
#   NOT founded IDs function 
def returnNotMatches(a, b): 
    return [x for x in a if x not in b] 
 
#   UniProt IDs not founded 
uniprot_id_notfound = returnNotMatches(ensembl_id, ensembl_id_2) 
 
# --------------------------------------------------------------- 
# ENST-UniProt df 
# --------------------------------------------------------------- 
#   Save ENS-UniProt IDs in a df 
ens_up_df = pd.DataFrame.from_dict(uniprot_dic, orient='index').reset_index() 
ens_up_df.rename(columns={'index': 'ENST', 0 :'SP_PRIMARY'}, inplace=True) 
 
# --------------------------------------------------------------- 
# Merge Data 
# --------------------------------------------------------------- 
# Merge S_aa_position file (COSMIC y BRCA-GDC) with ENS-UniProt ID (COSMIC) 
# by ENST, add UniProt column 
ens_S_df = pd.read_csv('./Breast-S_freq.csv', sep=',', dtype = np.str) # From 2-
Somatic_TSV.R 
ens_up_S_df = pd.merge(ens_S_df, ens_up_df, on=['ENST', 'ENST']) 
 
# --------------------------------------------------------------- 
# Save Data 
# --------------------------------------------------------------- 
ens_up_S_df.to_csv('/home/people/carlsa/TFM/Breast/Breast-S_freq-UP.csv', sep='\t', index= 
False) 
print('Breast-S_freq-UP: ',len(ens_up_S_df)) # Used in 6-PDB_S.R 
 
fin_time = time() 
print('Donde!') 
print('Time: ', round(fin_time - ini_time, 6), "seconds") 
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Annex V 
## 4- ENSP_PDB_NS.py 
# --------------------------------------------------------------- 
## DTU - Department of Bio and Health Informatics 
## 2017 
## Carmen Saenz 
## 
## 1. Load libraries 
## 2. Load data - Ensembl ID and mutation counts non-synonymous mutations 
## 3. Filter data 
## 4. Merge data 
## 5. Save data 
## 
# --------------------------------------------------------------- 
# Load Libraries 
# --------------------------------------------------------------- 
 
from bioservices import UniProt 
import numpy as np 
import pandas as pd 
from time import time 
 
ini_time = time() 
# --------------------------------------------------------------- 
# Load Data 
# --------------------------------------------------------------- 
Non_synonymous_df = pd.read_csv('./EnsemblP_ID.csv', sep='\t') #From 1-Breast_MAF.R 
 
#   Convert ENSP ID column to a list 
ensembl_id = Non_synonymous_df['ENSP_ID'].tolist() 
 
# --------------------------------------------------------------- 
# ENSP in UniProt 
# --------------------------------------------------------------- 
u = UniProt(verbose=False) 
 
#   ID mapping UniProt 
uniprot_id = u.mapping(fr = 'ENSEMBL_PRO_ID', to ='ACC', query = ensembl_id) 
 
#   Select only UniProt IDs 
uniprot_dic = {} 
uniprot_list = [] 
ensembl_id_2 = [] 
 
for element in uniprot_id: 
    uniprot_dic[element] = uniprot_id[element][0] 
    id = uniprot_id[element][0] 
    uniprot_list.append(id) 
    ensembl_id_2.append(element) 
 
uniprot_inv_dic = {v: k for k, v in uniprot_dic.items()} 
 
#   Save only non duplicate UniProt IDs 
uniprot_list = set(uniprot_list) 
 
#   NOT founded IDs function 
def returnNotMatches(a, b): 
    return [x for x in a if x not in b] 
 
#   UniProt IDs not founded 
uniprot_id_notfound = returnNotMatches(ensembl_id, ensembl_id_2) 
 
# --------------------------------------------------------------- 
# ENS-UniProt Df 
# --------------------------------------------------------------- 
#   Save ENS-UniProt IDs in a Df 
ens_up_df = pd.DataFrame.from_dict(uniprot_dic, orient='index').reset_index() 
ens_up_df.rename(columns={'index': 'ENSP', 0 :'SP_PRIMARY'}, inplace=True) 
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print ('ENS_UP') 
 
# --------------------------------------------------------------- 
# Merge Data 
# --------------------------------------------------------------- 
# Merge NS_aa_position file (Breast data) with ENS-UniProt ID (Breast data) 
# by ENSP, add UniProt column 
 
ens_NS_df = pd.read_csv('./Breast-NS_freq.csv', sep=',', dtype = np.str) # From 1-
Breast_MAF.R 
print('Breast-NS_freq: ',len(ens_NS_df)) 
 
# --------------------------------------------------------------- 
# Save Data 
# --------------------------------------------------------------- 
ens_up_NS_df = pd.merge(ens_NS_df, ens_up_df, on=['ENSP', 'ENSP']) 
ens_up_NS_df.to_csv('./Breast-NS_freq-UP.csv', sep='\t', index= False) 
print('Breast-NS_freq-UP: ',len(ens_up_NS_df)) #Used in 5-PDB_NS.R 
 
fin_time = time() 
print('Done!') 
print('Time: ', round(fin_time - ini_time, 6), "seconds") 
 
Annex VI 
 
## 5- PDB_NS.R 
###################################################################  
## DTU - Department of Bio and Health Informatics 
## 2017 
## Carmen Saenz 
## 
## 1. Load libraries 
## 2. Load data - RCSB and SIFTS files 
## 3. Map mutation to PDB structures 
## 4. Save data 
## 
###################################################################  
# Load Libraries 
################################################################### 
# Load required libraries but suppressing the Package Startup Messages (this is in case you 
want to embed this inside  
# an automated script) to avoid flooding the terminal with non interesting messages. 
suppressPackageStartupMessages(library(dplyr)) 
library(dplyr) 
###################################################################  
# Set directory 
################################################################### 
setwd() 
 
###################################################################  
# Load Data 
###################################################################  
###                  RCSB and SIFTS files                       ### 
###################################################################  
start.time <- Sys.time() 
 
## PDB df filter by Homo sapiens from RCSB (https://www.rcsb.org/pdb) 
pdb_Hs <- read.csv(file="./PDB_Hs/PDB_Hs.csv", sep = ',') 
pdb_Hs <- pdb_Hs[pdb_Hs$Taxonomy.ID == '9606',]  
pdb_Hs <- select(pdb_Hs, PDB.ID, Chain.ID, Exp..Method, Resolution) 
colnames(pdb_Hs) <- c("PDB", "CHAIN", "Exp_Method", "Resolution") 
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pdb_Hs$wt <- 'mutant' 
 
## PDB df tag wild type in wt column from RCSB 
pdb_wild_ID <- read.table(file="./Data/PDB_Hs/PDB_wildtypeID.txt", sep = ',') 
colnames(pdb_wild_ID)[1] <- 'ID' 
pdb_Hs$wt[(as.vector(pdb_Hs$PDB) %in% as.vector(pdb_wild_ID$ID))]='wt' 
levels(pdb_Hs$PDB) <- tolower(levels(pdb_Hs$PDB)) 
 
## Read tsv file with first and last positions of the proteins in the PDB structures from 
SIFTS 
## https://www.ebi.ac.uk/pdbe/docs/sifts/quick.html 
pdb_pos <- read.table(file="./Data/SIFTS/pdb_chain_uniprot.tsv", skip = 1, header = TRUE, 
sep = '\t') 
 
## MERGE Homo sapiens PDB info (method) and SIFTS file (positions) 
new = pdb_Hs[match(as.vector(pdb_pos$PDB),as.vector(pdb_Hs$PDB)),] 
pdb_data = cbind(pdb_pos,new) 
 
## Match one mutation with one PDB file 
mutation <- read.table(file="./Breast-NS_freq-UP.csv", header = TRUE, sep = '\t') #From 4-
ENSP_PDB_NS.py 
print(paste('Breast-NS_freq-UP:', nrow(mutation))) 
 
###################################################################  
# Map mutations to PDB structures 
###################################################################  
pdb_pos_wt = pdb_data 
listUP=unique(pdb_pos_wt$SP_PRIMARY) 
mutation$best_pdb = "none" 
mutation$Chain = "none" 
mutation$Exp.Method = "none" 
mutation$Resolution = "none" 
mutation$PDB_beg = "none" 
mutation$PDB_end = "none" 
mutation$UP_beg = "none" 
mutation$UP_end = "none" 
mutation$PDB_mpos = "none" 
mutation$PDB_aapos = "none" 
 
x <- sapply(mutation, is.factor) 
mutation[x] <- lapply(mutation[x], as.character) 
 
x <- sapply(pdb_pos_wt, is.factor) 
pdb_pos_wt[x] <- lapply(pdb_pos_wt[x], as.character) 
 
for (i in (1:nrow(mutation))){ 
  print(i) 
  #print (mutation$SP_PRIMARY[i]) 
  pdb_up = pdb_pos_wt[pdb_pos_wt$SP_PRIMARY == mutation$SP_PRIMARY[i],] 
  #print (pdb_up) 
  if (nrow(pdb_up)==0){ 
    next 
  } 
  else { 
    filter=c() 
    for (x in (1:nrow(pdb_up))){ 
      filter=c(filter,((mutation$prot_position[i] > pdb_up$SP_BEG[x]) & 
(mutation$prot_position[i] < pdb_up$SP_END[x]))) 
    } 
    pdb_up_pos = pdb_up[filter,] 
  } 
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  if (nrow(pdb_up_pos)==0){ 
    next 
  } 
  else{ 
    ranges=pdb_up_pos$SP_END-pdb_up_pos$SP_BEG 
    index=which(ranges==max(pdb_up_pos$SP_END-pdb_up_pos$SP_BEG)) 
    pdb_up_pos_range=pdb_up_pos[index,] 
  }    
  # Select PDB structure between more than one possibility:  
  # Experimental method: X-ray  
  # Highest resolution (lowest value) 
  # Longer protein sequence (highest difference between begining and ending protein 
sequence positions) 
  if ((nrow(pdb_up_pos_range)>1) & ("X-RAY" %in% pdb_up_pos_range$Exp_Method)){ 
    indexExp=which(pdb_up_pos_range$Exp_Method=="X-RAY DIFFRACTION") 
    pdb_up_pos_range_exp=pdb_up_pos_range[indexExp,] 
     
    if (nrow(db_up_pos_range_exp)>1){ 
      res=pdb_up_pos_range_exp$Resolution 
      indexRes=which(res==min(res)) 
      pdb_up_pos_range_exp_res=db_up_pos_range_exp[indexRes,] 
       
      mutation$best_pdb[i] = pdb_up_pos_range_exp_res$PDB 
      mutation$Chain[i] = pdb_up_pos_range_exp_res$CHAIN[1] 
      mutation$Exp.Method[i] = pdb_up_pos_range_exp_res$Exp_Method 
      mutation$Resolution[i] = pdb_up_pos_range_exp_res$Resolution 
      mutation$PDB_beg[i] = pdb_up_pos_range_exp_res$RES_BEG[1] 
      mutation$PDB_end[i] = pdb_up_pos_range_exp_res$RES_END[1] 
      mutation$UP_beg[i] = pdb_up_pos_range_exp_res$SP_BEG[1] 
      mutation$UP_end[i] = pdb_up_pos_range_exp_res$SP_END[1] 
      mutation$PDB_mpos[i] = ((as.integer(mutation$PDB_beg[i])-
as.integer(mutation$UP_beg[i])) +  
                                (as.integer(mutation$prot_position[i]))) 
      mutation$PDB_aapos[i] = paste(toupper(mutation$aa[i]),mutation$PDB_mpos[i], sep = "") 
    } 
     
    else{ 
      mutation$best_pdb[i] = pdb_up_pos_range_exp$PDB 
      mutation$Chain[i] = pdb_up_pos_range_exp$CHAIN[1] 
      mutation$Exp.Method[i] = pdb_up_pos_range_exp$Exp_Method 
      mutation$Resolution[i] = pdb_up_pos_range_exp$Resolution 
      mutation$PDB_beg[i] = pdb_up_pos_range_exp$RES_BEG[1] 
      mutation$PDB_end[i] = pdb_up_pos_range_exp$RES_END[1] 
      mutation$UP_beg[i] = pdb_up_pos_range_exp$SP_BEG[1] 
      mutation$UP_end[i] = pdb_up_pos_range_exp$SP_END[1] 
      mutation$PDB_mpos[i] = ((as.integer(mutation$PDB_beg[i])-
as.integer(mutation$UP_beg[i])) +  
                                (as.integer(mutation$prot_position[i]))) 
      mutation$PDB_aapos[i] = paste(toupper(mutation$aa[i]),mutation$PDB_mpos[i], sep = "") 
    } 
  } 
  else{ 
    pdb_up_pos_range=pdb_up_pos[(index[1]),] 
    mutation$best_pdb[i] = pdb_up_pos_range$PDB[1] 
    mutation$Chain[i] = pdb_up_pos_range$CHAIN[1] 
    mutation$Exp.Method[i] = pdb_up_pos_range$Exp_Method[1] 
    mutation$Resolution[i] = pdb_up_pos_range$Resolution[1] 
    mutation$PDB_beg[i] = pdb_up_pos_range$RES_BEG[1] 
    mutation$PDB_end[i] = pdb_up_pos_range$RES_END[1] 
    mutation$UP_beg[i] = pdb_up_pos_range$SP_BEG[1] 
    mutation$UP_end[i] = pdb_up_pos_range$SP_END[1] 
    mutation$PDB_mpos[i] = ((as.integer(mutation$PDB_beg[i])-
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as.integer(mutation$UP_beg[i])) +  
                              (as.integer(mutation$prot_position[i]))) 
    mutation$PDB_aapos[i] = paste(toupper(mutation$aa[i]),mutation$PDB_mpos[i], sep = "") 
     
  } 
   
} 
 
###################################################################  
# Save data 
###################################################################  
# Save mutation data mapped with PDB information 
write.csv(mutation, "./Breast-NS_freq-UP-PDB.csv", row.names = FALSE) 
print(paste('Breast-NS_freq-UP-PDB:', nrow(mutation))) 
 
# PDB data 
PDB_list_NS <- select(mutation,best_pdb,Chain) 
colnames(PDB_list_NS) <- c('ID', 'Chain') 
 
# sort file  
PDB_list_NS <- PDB_list_NS[order(PDB_list_NS$ID, PDB_list_NS$Chain),] 
PDB_list_NS <- (unique(PDB_list_NS)) 
PDB_list_NS <-PDB_list_NS [! PDB_list_NS$ID %in% 'none',] 
 
# Save PDB list to download PDB files (6-PDB-download.py) 
PDB_id_NS <- data.frame("ID" = PDB_list_NS$ID) 
PDB_id_NS  <- unique(PDB_id_NS) 
write.csv(PDB_id_NS, "./PDB_ID_NS.csv", row.names = FALSE) 
print(paste('PDB_ID_NS:', nrow(PDB_id_NS))) 
 
# Save PDB-chain list to calculate 3D clusters (7-Euclidean_distance.py) 
write.csv(PDB_list_NS, "./PDB_Chain_NS.csv", row.names = FALSE) 
print(paste('PDB_Chain_NS.csv:', nrow(PDB_list_NS))) 
 
end.time <- Sys.time() 
time.taken <- end.time - start.time 
print('Done!') 
print(paste('Time:', time.taken,'seconds')) 
 
Annex VII 
 
## 7- PDB_download.py 
# --------------------------------------------------------------- 
## DTU - Department of Bio and Health Informatics 
## 2017 
## Carmen Saenz 
## 
## 1. Load libraries 
## 2. Load data - PDB IDs 
## 3. Download data 
## 5. Save data 
## 
# --------------------------------------------------------------- 
# Load Libraries 
# --------------------------------------------------------------- 
import os 
from Bio.PDB import * 
from bioservices import UniProt 
import numpy as np 
import pandas as pd 
from time import time 
import os.path as path 
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# --------------------------------------------------------------- 
# Load Data 
# --------------------------------------------------------------- 
PDB_ID = pd.read_csv('./PDB_ID_NS.csv') # From 5-PDB_NS.R 
#   Convert ENSP ID column to a list 
PDB_IDList = PDB_ID.ID.tolist() 
 
# --------------------------------------------------------------- 
# 
# Download ans Save PDB files (.cif format) 
# 
# --------------------------------------------------------------- 
 
ini_time_total = time() 
not_download = list() 
for i in range(0,  len(PDB_IDList)): 
    name = PDB_IDList[i] 
    print('----------------------------------------------------------------') 
    print(name) 
    file = '/home/people/carlsa/TFM/Breast/PDB2/' + name + '.cif' 
    if path.exists(file): 
        print('Preload file:', name) 
        print((i + 1), '/', len(PDB_IDList), ) 
        continue 
 
    else: 
        print('Loading file: ', name) 
        ini_time = time() 
        pdbl = PDBList() 
        
pdbl.retrieve_pdb_file(pdb_code=name,file_format="mmCif",pdir="/home/people/carlsa/TFM/Brea
st/PDB2/") 
        if path.exists(file): 
            print('Loaded file: ', name) 
        else: 
            print('ERROR. Unloaded file: ', name) 
            not_download.append(name) 
        fin_time = time() 
        print('Time: ', round(fin_time - ini_time, 6), "seg") 
        print ((i+1), '/', len(PDB_IDList),) 
print ('----------------------------------------------------------------') 
print ('NOT downloaded PDB files: ', not_download) 
not_download_df = pd.DataFrame(not_download, columns=["PDB"]) 
# PDB files that cannot be downloaded 
not_download_df.to_csv('./Error_PDB.csv', sep='\t', index= False) 
 
fin_time_total = time() 
print('Total time : ', round(fin_time_total - ini_time_total, 3), "seg") 
Annex VIII 
# 8- Euclidean_dist.py 
#  Euclidean distance computation to generate 3D protein clusters 
# we used atom coordinates from PDB.cif files 
# --------------------------------------------------------------- 
## DTU - Department of Bio and Health Informatics 
## 2017 
## Carmen Saenz 
## 
## 1. Load libraries 
## 2. Load data - PDB files 
## 3. Euclidean distance computation 
## 5. Save data 
## 
# --------------------------------------------------------------- 
# Load Libraries 
# --------------------------------------------------------------- 
import os 
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import pandas as pd 
import numpy as np 
from time import time 
import os.path as path 
 
# --------------------------------------------------------------- 
# Load Data 
# --------------------------------------------------------------- 
PDB_df = pd.read_csv('./PDB_Chain_NS.csv',  sep=',') #From 5-PDB_NS.R 
 
#   Convert ENSP ID column to a list 
PDB_ID = PDB_df['ID'].tolist() 
 
# --------------------------------------------------------------- 
# Euclidean distance computationLoad Data 
# --------------------------------------------------------------- 
not_pdb = list() 
for i in range(0, len(PDB_df)): 
    name_pdb = PDB_ID[i] 
    chain = str(PDB_df['Chain'][i]) 
    print('----------------------------------------------------------------') 
    print('Loading file: ', name_pdb) 
    print(i, '/', (len(PDB_df)-1)) 
    PDB_file ='/home/people/carlsa/TFM/Breast/PDB/' + name_pdb +'.cif' 
    name_pdb = name_pdb.upper() 
    eucl_file = '/home/people/carlsa/TFM/Breast/3D_cluster/' + name_pdb + '_' + chain + 
'.txt' 
    if path.exists(eucl_file): 
        print('Pre-calculated 3D cluster for file :', (name_pdb + '_' + chain)) 
        continue 
 
    if not path.exists (PDB_file): 
        print('ERROR. File ', name_pdb, ' NOT found') 
        not_pdb.append(name_pdb) 
        continue 
    #Select the variables in PDB.cif file 
    else : 
        from Bio.PDB.MMCIFParser import MMCIFParser 
        parser = MMCIFParser() 
        from Bio.PDB.MMCIF2Dict import MMCIF2Dict 
        try: 
            mmcif_dict = MMCIF2Dict(PDB_file) 
            # .cif files are indexed 
            # Select coulmns of interest 
            # Add each column to a variable 
 
            name = mmcif_dict['_entry.id'] 
            print(name) 
 
            # Strands of the protein in the PDB file 
            strand = mmcif_dict['_entity_poly.pdbx_strand_id'] 
            print('strand: ', strand) 
 
            #name of the protein 
            entity_id = mmcif_dict['_entity_poly.entity_id'] 
            entity_id_2 = mmcif_dict['_atom_site.label_entity_id'] 
            strct_letter = mmcif_dict['_struct_asym.id'] 
            strct_number = mmcif_dict['_struct_asym.entity_id'] 
            loop_number = mmcif_dict['_atom_site.pdbx_PDB_model_num'] 
            group = mmcif_dict['_atom_site.group_PDB'] 
            # name of the atom of the amino-acid 
            atom = mmcif_dict['_atom_site.label_atom_id'] 
            # symbol of the atom 
            prog_num = mmcif_dict['_atom_site.id'] 
            alt_conformation = mmcif_dict['_atom_site.label_alt_id'] 
            # amino-acid 
            resid = mmcif_dict['_atom_site.label_comp_id'] 
            #amino-acid residue number 
            pos = mmcif_dict['_atom_site.label_seq_id'] 
            # amino-acid residue number in PDB file 
            pos_pymol = mmcif_dict['_atom_site.auth_seq_id'] 
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            # name of the aminacid 
            string = mmcif_dict['_atom_site.label_asym_id'] 
            #Residue coordinates 
            x_list = mmcif_dict['_atom_site.Cartn_x'] 
            y_list = mmcif_dict['_atom_site.Cartn_y'] 
            z_list = mmcif_dict['_atom_site.Cartn_z'] 
 
            if type(strand) == str: 
                aux = list() 
                aux.append(strand) 
                strand = aux 
 
            # Look for the correct strand in the PDB file: 
            flag = 0 
            chain_match = 0 
            for j in range(0, len(entity_id)): 
                if flag == 1: 
                    break 
                else: 
                    strand_pdb = list(strand[j].split(',')) 
                    for k in range(0, len(strand_pdb)): 
                        if strand_pdb[k] == chain: 
                            flag = 1 
                            chain_match = entity_id[j] 
                            print('Match Chain - Entity id: ', chain, ', ', chain_match) 
                            break 
 
            # Crate a data frame with all the mutations and coordinates information 
            df_coord = pd.DataFrame({"Group": group, "Alt_Conformation": alt_conformation, 
"ATOM": atom, "Residue": resid, "Position": pos, "Position_PyMOL": pos_pymol, "String": 
string, "Entity_id": entity_id_2, "Loop_number": loop_number, "coord_x": x_list, "coord_y": 
y_list, "coord_z": z_list}) 
 
 
            string_u = strct_letter[strct_number.index(chain_match)] 
            loop_number_2 = df_coord.Loop_number.unique() 
            # Filter dataframe by CA (alfa carbons), chain, string,.... 
            df_coord = df_coord.loc[df_coord['Group'] == 'ATOM'] 
            df_coord = df_coord.loc[df_coord['ATOM'] == 'CA'] 
            df_coord = df_coord.loc[df_coord['Entity_id'] == chain_match] 
            df_coord = df_coord.loc[df_coord['String'] == string_u] 
            df_coord = df_coord.loc[df_coord['Loop_number'] == loop_number_2[0]] 
            df_coord = df_coord.loc[df_coord['Alt_Conformation'].isin(['.', 'A'])] 
 
 
            # EUCLIDEAN DISTANCE COMPUTATION 
            # Create a data frame to save euclidean distance between two alfa carbons (CA) 
            # Filter by residue index, no euclidean distance between same residue 
            # Filter by euclidean distance value below 15 Amstrongs --> 3D clusters 
            df_dist = pd.DataFrame(columns=('Chain', 'Entity_id', 'string_x', 'aa_x', 
'pos_x', 'string_y', 'aa_y', 'pos_y', 
                                            'euclidean_dist', 'pos_PyMOLx', 'pos_PyMOLy')) 
 
            ini_time = time() 
            for x in range(len(df_coord)): 
                for y in range(len(df_coord)): 
                    if (df_coord.index[x] != df_coord.index[y]): 
                        x_cor_1 = float(df_coord.coord_x.iloc[x]) 
                        y_cor_1 = float(df_coord.coord_y.iloc[x]) 
                        z_cor_1 = float(df_coord.coord_z.iloc[x]) 
                        x_cor_2 = float(df_coord.coord_x.iloc[y]) 
                        y_cor_2 = float(df_coord.coord_y.iloc[y]) 
                        z_cor_2 = float(df_coord.coord_z.iloc[y]) 
                        x_diff = x_cor_1 - x_cor_2 
                        y_diff = y_cor_1 - y_cor_2 
                        z_diff = z_cor_1 - z_cor_2 
                        euclidean_diff = (((x_diff ** 2) + (y_diff ** 2) + (z_diff ** 2)) 
** 0.5) 
                        #print(euclidean_diff) 
                        if euclidean_diff <= float(15): 
                            df_dist.loc[len(df_dist)] = [chain, df_coord.Entity_id.iloc[x], 
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df_coord.String.iloc[x], df_coord.Residue.iloc[x], df_coord.Position.iloc[x], 
df_coord.String.iloc[y], df_coord.Residue.iloc[y], df_coord.Position.iloc[y], 
euclidean_diff,df_coord.Position_PyMOL.iloc[x], df_coord.Position_PyMOL.iloc[y]] 
 
            fin_time = time() 
            print('Done!') 
            print('Time: ', round(fin_time - ini_time, 6), "seg") 
# --------------------------------------------------------------- 
# Save Data 
# --------------------------------------------------------------- 
            df_dist.to_csv('./3D_cluster/' + name + '_' + chain + '.txt', sep='\t', 
index=False) #Used in 9-3Dcluster.R 
        except ValueError: 
            print('ERROR in file ', name_pdb) 
            not_pdb.append(name_pdb) 
            continue 
 
print ('----------------------------------------------------------------') 
print ('NOT founded PDB files: ', not_pdb) 
not_pdb_df = pd.DataFrame(not_pdb, columns= ["PDB"]) 
not_pdb_df.to_csv("./euclidistance_ERROR.csv", sep='\t',index=False) 
Annex IX 
## 9-3Dcluster.R 
# Identify mutated residues in 3D protein clusters and asign NS ans S mutations counts 
###################################################################  
## DTU - Department of Bio and Health Informatics 
## 2017 
## Carmen Saenz 
## 
## 1. Load libraries 
## 2. Load data  
## 3. 3D protein cluster computation 
## 4. Save data 
## 
###################################################################  
# Load Libraries 
################################################################### 
suppressPackageStartupMessages(library(dplyr)) 
library(dplyr) 
###################################################################  
# Set directory 
################################################################## 
setwd("") 
 
###################################################################  
# Load Data 
###################################################################  
## PDB 3D cluster file 
pdb_idlist <- read.csv(file="./PDB_Chain_NS.csv", sep = ',') # From 5-PDB_NS.R 
mutation_df_NS <- fread(file = "./Breast-NS_freq-UP-PDB.csv", sep = ',') # From 5-PDB_NS.R 
mutation_df_S <- fread(file = "./Breast-S_freq-UP-PDB.csv", sep = ',') # From 6-PDB_S.R 
 
###################################################################  
#3D protein cluster computation 
###################################################################  
# Identify mutated residues in 3D clusters and asign NS and S mutant counts 
error_list = c() 
for (i in (1:nrow(pdb_idlist))){ 
  i = 4 
  id = as.vector(pdb_idlist$ID[i]) 
  chain = as.vector(pdb_idlist$Chain[i]) 
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  ID = toupper(id) 
  filename = paste(ID,chain, sep = "_") 
  input = paste("./3D_cluster/",filename,".txt", sep = "") 
  output_freq = paste("./3D_cluster_freq/", filename, "_freq", ".txt", sep = "") 
  print ('------------------------------------------------------------') 
  print(paste('Loading file:', filename)) 
  if (file.exists(output_freq)){ 
    print(paste('Pre-calculated 3D cluster for file:', filename)) 
    print(paste(i, '/', nrow(pdb_idlist))) 
    next 
  } else{ 
    print(paste(i, '/', nrow(pdb_idlist))) 
    if (!file.exists(input)){ 
      error_list = c(error_list, filename) 
      print(paste('File', filename, 'NOT found')) 
      next 
    } else { 
      pdb_3D <- read.csv(file=input, sep = '\t') 
      print(paste('Calculating 3D cluster for file:', filename)) 
      # Residue position in PDB 
      res_pos_x = paste(pdb_3D$aa_x,pdb_3D$pos_x,"_",pdb_3D$Chain, sep = "") 
      pdb_3D$res_pos_x <- res_pos_x 
      res_pos_y = paste(pdb_3D$aa_y,pdb_3D$pos_y,"_",pdb_3D$Chain, sep = "") 
      pdb_3D$res_pos_y <- res_pos_y 
       
      # Residue position in PyMOL 
      res_pos_PyMOLx = paste(pdb_3D$aa_x,pdb_3D$pos_PyMOLx,"_",pdb_3D$Chain, sep = "") 
      pdb_3D$res_pos_PyMOLx <- res_pos_PyMOLx 
      res_pos_PyMOLy = paste(pdb_3D$aa_y,pdb_3D$pos_PyMOLy,"_",pdb_3D$Chain, sep = "") 
      pdb_3D$res_pos_PyMOLy <- res_pos_PyMOLy 
    } 
  } 
  dataset = pdb_3D 
  res = unique(dataset$res_pos_x) 
  res_PyMOL = unique(dataset$res_pos_PyMOLx) 
  cluster = list() 
  cluster_PyMOL = list() 
  for (i in (1:length(res))){ 
    # Cluster file, all residue names + position in PDB for each cluster  
    res_clust = res[i] 
    pdb_clust = dataset[dataset$res_pos_x == res_clust,] 
    cluster = c(cluster, list(c(res_clust,pdb_clust$res_pos_y))) 
    len_cluster <- sapply(cluster, length) 
    max_cluster <- seq_len(max(len_cluster)) 
    matrix_cluster <- t(sapply(cluster, "[", i=max_cluster)) 
    output_cluster = paste("./3D_cluster_freq/", filename, "_cluster", ".txt", sep = "") 
    write.csv(matrix_cluster, output_cluster, row.names = FALSE) 
     
    # Cluster PyMOL file, all residue names + position in PyMOL for each cluster  
    res_clust_PyMOL = res_PyMOL[i] 
    pdb_clust_PyMOL = dataset[dataset$res_pos_PyMOLx == res_clust_PyMOL,] 
    cluster_PyMOL = c(cluster_PyMOL, 
list(c(res_clust_PyMOL,pdb_clust_PyMOL$res_pos_PyMOLy))) 
    len_cluster_PyMOL <- sapply(cluster_PyMOL, length) 
    max_cluster_PyMOL <- seq_len(max(len_cluster_PyMOL)) 
    matrix_cluster_PyMOL <- t(sapply(cluster_PyMOL, "[", i=max_cluster_PyMOL)) 
    output_cluster_2 = paste("./3D_cluster_freq/", filename, "_clusterPyMOL", ".txt", sep = 
"") 
    write.csv(matrix_cluster_PyMOL, output_cluster_2, row.names = FALSE) 
     
    # Cluster lenght file 
    summary(cluster) 
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    cluster_summary = summary(cluster) 
    cluster_len = as.data.frame.matrix(cluster_summary) 
    cluster_len = as.vector(cluster_len$Length) 
    output_len = paste("./3D_cluster_freq/", filename, "_lenght", ".txt", sep = "") 
    write.csv(cluster_len, output_len, row.names = FALSE) 
  } 
   
  # NS mutant counts  
  mut_pdb_NS=mutation_df_NS[((mutation_df_NS$best_pdb==id) & 
(mutation_df_NS$Chain==chain)),] 
  freq_NS =list() 
  print(paste('Calculating Non-synonymous mutation frequencies for file:', filename)) 
  for (i in (1:nrow(cluster_summary))){ 
    temp_res_NS=c() 
    for (r in (cluster[[i]])){ 
      if (unlist(strsplit(r,"_"))[1] %in% as.vector(mut_pdb_NS$PDB_aapos)){ 
        for (y in (1:nrow(mut_pdb_NS))){ 
          if (unlist(strsplit(r,"_"))[1]==as.vector(mut_pdb_NS$PDB_aapos[y])){ 
            
temp_res_NS=c(temp_res_NS,as.integer(unlist(as.vector(mut_pdb_NS$Mutation_count[y])))[1]) 
          } 
        } 
      } 
      else{ 
        temp_res_NS=c(temp_res_NS,0) 
      } 
    } 
    freq_NS = c(freq_NS,list(temp_res_NS)) 
  } 
  len_freq_NS <- sapply(freq_NS, length) 
  max_freq_NS <- seq_len(max(len_freq_NS)) 
  matrix_freq_NS <- t(sapply(freq_NS, "[", i=max_freq_NS)) 
  output_freq_NS = paste("./3D_cluster_freq/", filename, "_freq_NS", ".txt", sep = "") 
  write.csv(matrix_freq_NS, output_freq_NS, row.names = FALSE) 
  summary(freq_NS) 
  freq_NS_summary = summary(freq_NS)  
   
  sum_list_NS=c() 
  for (t in (1:nrow(cluster_summary))){ 
    sum_list_NS=c(sum_list_NS,sum(freq_NS[[t]])) 
  } 
  print ('Summary') 
  print (summary(sum_list_NS)) 
  print (nrow(mut_pdb_NS)) 
   
   
  # S mutant counts  
  mut_pdb_S=mutation_df_S[((mutation_df_S$best_pdb==id) & (mutation_df_S$Chain==chain)),] 
  freq_S =list() 
  print(paste('Calculating Synonymous mutation frequencies for file:', filename)) 
  for (i in (1:nrow(cluster_summary))){ 
    temp_res_S=c() 
    for (r in (cluster[[i]])){ 
      if (unlist(strsplit(r,"_"))[1] %in% as.vector(mut_pdb_S$PDB_aapos)){ 
        for (y in (1:nrow(mut_pdb_S))){ 
          if (unlist(strsplit(r,"_"))[1]==as.vector(mut_pdb_S$PDB_aapos[y])){ 
            
temp_res_S=c(temp_res_S,as.integer(unlist(as.vector(mut_pdb_S$Mutation_count[y])))[1]) 
          } 
        } 
      } 
      else{ 
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        temp_res_S=c(temp_res_S,0) 
      } 
    } 
    freq_S = c(freq_S,list(temp_res_S)) 
  } 
  len_freq_S <- sapply(freq_S, length) 
  max_freq_S <- seq_len(max(len_freq_S)) 
  matrix_freq_S <- t(sapply(freq_S, "[", i=max_freq_S)) 
  output_freq_S = paste("./3D_cluster_freq/", filename, "_freq_S", ".txt", sep = "") 
  write.csv(matrix_freq_S, output_freq_S, row.names = FALSE) 
  summary(freq_S) 
  freq_S_summary = summary(freq_S)  
   
  sum_list_S=c() 
  for (t in (1:nrow(cluster_summary))){ 
    sum_list_S=c(sum_list_S,sum(freq_S[[t]])) 
  } 
  print ('Summary') 
  print (summary(sum_list_S)) 
  print (nrow(mut_pdb_S)) 
  frequencies = data.frame(freq_NS = sum_list_NS, freq_S = sum_list_S) 
  write.csv(frequencies, output_freq, row.names = FALSE) 
   
} 
print ('------------------------------------------------------------') 
print (paste('Input files NOT found:', error_list)) 
write.csv(error_list, './Error_3Dcluster.csv', row.names = FALSE) 
 
end.time <- Sys.time() 
time.taken <- end.time - start.time 
print('Done!') 
print(paste('Time:', time.taken, 'seconds)) 
Annex X 
 
## 10-FreqLen.R 
###################################################################  
## DTU - Department of Bio and Health Informatics 
## 2017 
## Carmen Saenz 
## 
## 1. Load libraries 
## 2. Load data - Frequency of NS and S and cluster lenght 
## 3. Merge data 
## 4. Save as .RData 
## 
###################################################################  
# Load Libraries 
################################################################### 
suppressPackageStartupMessages(library(dplyr)) 
library(dplyr) 
library(stringr) 
###################################################################  
# Set directory 
################################################################### 
setwd("") 
 
###################################################################  
# Load Data 
###################################################################  
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###     Frequency of NS and S and cluster lenght file           ### 
###################################################################  
start.time <- Sys.time() 
 
pdb_list <- read.csv('./PDB_Chain_NS.csv') # From 5-PDB_NS.R 
 
###################################################################  
# Merge Data 
###################################################################  
# Create error list  
error_list = c() 
freq_len <- data.frame() 
for (i in (1:nrow(pdb_list))){ 
  id = as.vector(pdb_list$ID[i]) 
  chain = as.vector(pdb_list$Chain[i]) 
  ID = toupper(id) 
  filename = paste(ID,chain, sep = "_") 
  input = paste("./3D_cluster_freq_B/",filename,"_freq.txt", sep ="") 
  input_2 = paste("./3D_cluster_freq_B/",filename,"_lenght.txt", sep ="") 
  output = paste("./3D_cluster_freq_B/",filename,"_freqlen.txt", sep ="") 
  print ('------------------------------------------------------------') 
  print(paste('Loading file:', filename)) 
  if (file.exists(input) & file.exists(input_2)){ 
    freq_df <- read.csv(file=input) 
    len_df <- read.csv(file = input_2, col.names = "length") 
    freq_file <- data.frame(cluster = 1:nrow(freq_df)) 
    freq_file$PDB <- filename 
    freq_file$mut_count_NS <- freq_df$freq_NS 
    freq_file$mut_count_S <- freq_df$freq_S 
    freq_file$length <- len_df$length 
    write.csv(freq_file, output, row.names = FALSE) 
  } else { 
    error_list = c(error_list, filename) 
    print(paste('File', filename, 'NOT found')) 
    next 
  } 
  freq_len <- rbind(freq_len, freq_file) 
} 
 
###################################################################  
# Save Data 
###################################################################  
 
write.csv(freq_len, "./FreqLen.csv", row.names = FALSE) # used in 11-score.R 
print ('------------------------------------------------------------') 
print (paste('Input files NOT found:', error_list)) 
write.csv(error_list, './TFM_FreqLen_ERROR.csv', row.names = FALSE) 
 
end.time <- Sys.time() 
time.taken <- end.time - start.time 
print('Done!') 
print(paste('Time:', time.taken, 'seconds')) 
Annex XI 
 
## 11-Score.R 
###################################################################  
## DTU - Department of Bio and Health Informatics 
## 2017 
## Carmen Saenz 
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## 
## 1. Load libraries 
## 2. Load data - Frequency of NS and S and cluster lenght 
## 3. 3D cluster score computation 
## 4. Save as .RData 
## 
###################################################################  
# Load Libraries 
################################################################### 
suppressPackageStartupMessages(library(dplyr)) 
library(data.table) 
library(stringr) 
 
###################################################################  
# Set directory 
################################################################### 
setwd("") 
############################################################################### 
 
###################################################################  
# Load Data 
###################################################################  
###     Frequency of NS and S and cluster lenght file           ### 
###################################################################  
start.time <- Sys.time() 
 
# READ files 
mutcount = fread(file = "./FreqLen.csv", sep = ',') #(1125683 clusters) #From 10-FreqLen.R 
NS_mutation_df = fread(file = "./Breast-NS_freq-UP-PDB.csv", sep = ",") #From 5-PDB_NS.R 
S_mutation_df = fread(file = "./Breast-S_freq-UP-PDB.csv", sep = ",")#From 6-PDB_S.R 
 
library(dplyr) 
# Mutant counts 
mutcount = mutcount[order(-mut_count_NS,mut_count_S,length),] 
 
# Gene - PDB_Chain data frame 
gene_PDB_df = data.frame(gene = NS_mutation_df$Hugo_Symbol) 
gene_PDB_df$PDB_chain = paste(toupper(NS_mutation_df$best_pdb),NS_mutation_df$Chain, sep = 
"_")  
gene_PDB_df = unique(gene_PDB_df) 
gene_PDB_df = gene_PDB_df[!gene_PDB_df$PDB_chain == "NONE_none",] (#4317 rows,  
# there are 4289 PDB_Chain files, some of them (28) are used for different genes: CKMT1A 
and CKMT1B -> 1QK1_A) 
index = match(mutcount$PDB,gene_PDB_df$PDB_chain) 
 
###################################################################  
# 3D cluster score computation 
################################################################### 
# Match mutant counts with genes 
mutcount$gene = (gene_PDB_df$gene[index]) 
 
# CREATE new data frame for score calculations 
file_size = nrow(mutcount) 
score_file <- data.frame(index = 1:file_size) 
 
score_file$gene = mutcount$gene 
score_file$PDB = mutcount$PDB 
score_file$cluster = mutcount$cluster 
score_file$name = paste(mutcount$PDB,mutcount$cluster,sep = "_" ) 
score_file$mc_NS = mutcount$mut_count_NS 
score_file$mc_S = mutcount$mut_count_S 
score_file$length = mutcount$length 
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NSin = mutcount$mut_count_NS 
Sin = mutcount$mut_count_S 
 
cases_NS = unique(NS_mutation_df$Total_cases_GDC) 
cases_S = unique(S_mutation_df$Total_cases_COSMIC) 
 
# -------------------------------------------------- 
# S and NS frequency computation 
 
NStotal = 2*cases_NS*mutcount$length 
Stotal = 2*cases_S*mutcount$length 
cs_NS_v = (NSin/NStotal) 
cs_S_v = (Sin/Stotal) 
 
# Save values in a data frame 
score_file$cs_NS = cs_NS_v 
score_file$cs_S = cs_S_v 
# -------------------------------------------------- 
#Add 1 pseudo-count 
NSin1 = NSin  + 1  
Sin1 = Sin + 1 
cases_NS1 = cases_NS + 1 
cases_S1 = cases_S + 1 
  
NStotal1 = 2*cases_NS1*mutcount$length 
Stotal1 = 2*cases_S1*mutcount$length 
 
# S and NS frequency computation and save results in vectors 
cs_NS1_v = (NSin1/NStotal1) 
cs_S1_v = (Sin1/Stotal1) 
ratio1_v = (cs_NS1_v/cs_S1_v) 
logratio1_v =log2(cs_NS1_v/cs_S1_v) 
 
# Save values in a data frame 
score_file$cs_NS_1 = cs_NS1_v 
score_file$cs_S_1 = cs_S1_v 
score_file$ratio_1 = ratio1_v 
score_file$log2_ratio_1 = logratio1_v 
 
# -------------------------------------------------- 
#Add 0.5 pseudo-count 
NSin5 = NSin  +0.5 
Sin5 = Sin +0.5 
cases_NS5 = cases_NS + 0.5 
cases_S5 = cases_S + 0.5 
 
NStotal5 = 2*cases_NS5*mutcount$length 
Stotal5 = 2*cases_S5*mutcount$length 
 
# S and NS frequency computation and save results in vectors 
cs_NS5_v = (NSin5/NStotal5) 
cs_S5_v = (Sin5/Stotal5) 
ratio5_v = (cs_NS5_v/cs_S5_v) 
logratio5_v =log2(cs_NS5_v/cs_S5_v) 
 
# Save values in a data frame 
score_file$cs_NS_5 = cs_NS5_v 
score_file$cs_S_5 = cs_S5_v 
score_file$ratio_5 = ratio5_v 
score_file$log2_ratio_5 = logratio5_v 
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# -------------------------------------------------- 
#Add 1e-10 pseudo-count 
NSine = NSin  +1e-10 
Sine = Sin +1e-10 
cases_NSe = cases_NS + 1e-10 
cases_Se = cases_S + 1e-10 
 
NStotale = 2*cases_NSe*mutcount$length 
Stotale = 2*cases_Se*mutcount$length 
 
# S and NS frequency computation and save results in vectors 
cs_NSe_v = (NSine/NStotale) 
cs_Se_v = (Sine/Stotale) 
ratioe_v = (cs_NSe_v/cs_Se_v) 
logratioe_v = log2(cs_NSe_v/cs_Se_v) 
 
# Save values in a data frame 
score_file$cs_NS_e = cs_NSe_v 
score_file$cs_S_e = cs_Se_v 
score_file$ratio_e = ratioe_v 
score_file$log2_ratio_e = logratioe_v 
 
###################################################################  
# Save Data 
###################################################################  
 
write.csv(score_file, "./Score.txt", row.names=FALSE) # RESULTS 
print(paste('Total number of clusters:',nrow(score_file)))  
 
end.time <- Sys.time() 
time.taken <- end.time - start.time 
print('Done!') 
print(paste('Time:', time.taken, 'seconds')) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
